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Abstract
The pursuit of sensitive, non-invasive, and cost efficient diagnostic tools for early stage
disease detection have led to the development of sophisticated biosensor technologies for
proteomic studies. As these markers increase in complexity, the role of support substrates
grows increasingly important. Limitations in existing support substrates include the
potential for increased sensitivity, binding specificity, and bio-stability. Ideal support
substrates need to provide biocompatible and bioresistant surfaces, that offer high surface
areas for binding, and enables the incorporation of diverse chemistries. The use of peptoids
as the basis for the deposition of uniform microsphere coatings offers a mean to the
attainment of such characteristics. Specifically, it enables for the utilization of its unique
characteristics, namely, ease of synthesis and highly customizable side chain chemistries, in
order to create a robust, biocompatible surface.
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1. Introduction
Although knowledge of different types of cancer and their progression has grown
remarkably in the last decades, progress in the efforts has in large been hampered by the
technology to detect them at an early stage. This difficulty stems from the fact that the
diagnosis of a disease cannot be considered analogous to its detection. Diagnosis
predominantly follows the recognition of symptoms, and many of those initial symptoms
are often indicative of a number of diseases with similar features, rather than specific to the
one responsible. Most importantly however, cancer diagnosis often occurs too late, as
symptoms manifest themselves once tumors are considerably large and the disease
consequently widespread.
Mortality rates in cancer increase with disease progression. For this reason, it is at its
incipient stages of development that the therapeutic treatment of cancer presents its
greatest potential. However, these early stages are often asymptomatic, resulting in
delayed diagnoses of more advanced stages for which treatment is found often ineffective
[1]. Data from the Surveillance Epidemiology and End Results (SEER) Program of the
National Cancer Institute demonstrates the sharp contrast that exists in areas where tumor
growth can be more easily observed, and hence detected, as compared to internal organs
where it is much more difficult [2]. While the 5 year survival rate in skin cancer (91.5%)
and breast cancer (89.4%) paints a much more optimistic outlook, lung cancer (17.4%) and
pancreatic cancer (7.2%) drop a sobering dose of reality (http://seer.cancer.gov) [3]. The
identification of cancer by pathological techniques is reliant on the morphologic
assessment of tumor tissue. While this method is suitable for the identification of tumors
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that occur at certain accessible areas (cervix), this same type of assessment is not feasible
at other less accessible regions (ovaries), which hence hold much higher rates of mortality
[4]. While crucial for the current prognosis of cancer, these techniques unfortunately fall
short in providing the basis for the development of a technology that would allow for early
detection [5].
Early detection decreases the economic costs, extensiveness of the treatment, and
mortality associated with the disease [6]. The value of diagnostic technologies is
intrinsically related to accuracy and stage at which they are able to identify a disease.
Disease identification needs the existence of sensitive assays that can detect molecular
changes associated with the onset of the disease with high specificity. Early detection
requires the screening of asymptomatic populations in a minimally invasive manner and
with small sample volumes. Biomarker-based technologies offer promising means for the
attainment of these goals [4].
1.1. Biomarkers
Over the last decades, there has been an enormous effort to develop sensitive diseasespecific assays that can assist in therapeutic decision [1]. Biomarkers are molecular
indicators of a physiological status, and as a result can be assayed to provide information
on the state of a biological process [7]. The use of biomarkers is integral to cancer research
because of the unique association genomic changes in cancer cells have with the
progression of the disease [1]. Cancer biomarkers reflect genotoxicity, hyperproliferation,
hyperplasia, inflammation, mutations, altered patterns of gene and protein expression,
promoter methylation, and enzymatic changes produced by the disease or the host system
2

in response to the disease [5] [7]. Understanding these changes as natural identifiers of
disease progression will allow for the discovery of new biomarkers for (i) early detection,
(ii) diagnosis, (iii) prognosis of high-risk individuals, (iv) response to treatment and/or (v)
recurrence of the disease [8].
Progress in proteomic technologies have led to the discovery of novel biomarkers through
the assessment of proteome profiles in disease states [9]. In contrast to the genome, which
is rather more of a constant entity, the proteome represents a dynamic compilation of
diverse proteins that vary among different individuals, cell types, and pathophysiological
conditions [10]. While the genome comprises the genetic makeup of each cell, it provides
little information about their structure, interactions, modifications, cellular localization,
activities, biological function, and, potential involvement in the carcinogenic process [11].
In fact, gene activity and protein abundance show no reliable correlation [12]. The
biological roles of proteins are determined by post-translation modifications and
interactions such as glycosylation, phosphorylation, cleavage, crosslinking, oxidation or
reduction, and lipid attachment [13]. The complexity of these modifications has lead to the
realization that protein dynamics cannot be probed using genetics and DNA-based methods
[14]. Protein-based approaches provide a natural platform for these studies. They are
based on the identification of altered protein expression levels in disease states [15] [16].
Antibody-based arrays are also often utilized for diagnosis. Antibodies, being natural
binders of proteins, provide a means to compare and quantify protein levels in health and
disease [17]. Antibody platforms have been developed on monoclonal, polyclonal and
recombinant antibodies [13] [18] [19] [20] [21] [22] [23] [24] [25]. Antibodies are widely
utilized in protein detection because of the high specificity that is required in order to
3

identify a target [26]. Additionally, the relative structural uniformity of antibodies allows
for the utilization of single support surfaces.
Changes in post-translational modifications of protein structures have important roles in
disease progression, and thus if profiled correctly offer valuable information associated to
the disease. Glycosylation is one of many post-translational modifications, prevalent in over
50% of proteins [27]. Glycans are involved in recognition, adherence, motility, and
signaling processes [28] [29]. The potential as biomarkers is reflected by the occurrence of
cancer-associated glycans resultant from oncogenic altered glycosylation. Cancerassociated glycans are predominantly located on the surface of cells, and therefore ideal
targets for detection [30]. Glycans have been screening in human serum for diagnostic
purposes [31] [32] [33] [34] [35] and utilized for malignancy-identification for breast
cancer [35] and Hodgkin’s lymphoma [36].
1.2. Microarrays
While advances in technology continue to accelerate the discovery of potential biomarkers
[37] [38] [39], assessment of their true value for the screening of complex disease lags
behind. In fact, the approval rate of new clinical biomarkers is in decline [37]. A major
obstacle hampering biomarker validation is the intrinsic molecular heterogeneity that
exists across diverse populations and tumor tissues. To overcome this large variability,
validation technologies need to reproducibly analyze thousands of samples to effectively
assess assay performance [40]. Enzyme-linked immunosorbent assay (ELISA) microarray
technology can analyze a profile of biomarkers in parallel and, thus, has the sensitivity and
specificity necessary to accelerate the validation of clinical biomarkers [41] [42].
4

The concept of the ‘microspot’ assay was introduced by Ekins under the fundamental
premise that miniaturization would allow for the detection of analytes with higher
sensitivity than those of conventional macroscopic immunoassays [43] [44]. ELISA
microarray technology was developed in early 2000 [17] by combining protocols and
instrumentation for DNA microarrays and 96-well plate ELISA [45], yielding a robust and
automated platform of unmatched high-throughput sensitivity and reproducibility [46].
Antibody microarray technology has been utilized for the non-invasive detection of
disease-specific analytes in bodily fluids (serum, plasma, urine, tears) and tissues extracts
[47] for leukemia [48], breast cancer [49] [50] [51] [52], prostate cancer [53], pancreatic
cancer [54] [55], lung cancer [56] [57] [58], bladder cancer [47], colorectal cancer [59]
[60], cystic fibrosis [61], primary Sjogren's syndrome [62], psoriatic arthritis [63], as well
as congestive heart failure [64].
1.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Microarray
Enzyme-linked immunosorbent assay (ELISA) microarray technology has emerged as a
strong platform for the analysis of biomarkers. Advantages of this platform are associated
to the miniature nature of its design, which allows for the cost-effective and efficient
parallel screening of small volumes of precious clinical samples and expensive antibodies
in a high-throughput manner, thus enabling the study of large populations of samples
necessary for the identification and validation of biomarkers [45]. In addition, the assays
allow for the quantitative measurement of multiple proteins in complex biological fluids
over a large concentration range with high sensitivity and specificity [65]. Furthermore, its
similarity to ELISA protocols used routinely in clinical laboratories facilitates assay transfer
5

from the laboratory to clinical settings [66].
The capability to analyze multiple proteins in parallel offers many benefits. Aside from
practical benefits (time, cost, reagent consumption), parallel measurements are of great
scientific interest [13]. Multiplex studies allow for the screening of biomarkers to reveal
associations in proteins and disease states. Proteins interact in complex networks and
often have overlapping or complementary functions. Multiplex studies thus provide
experimental conditions that can portray a much more meaningful picture of a biological
state [13]. Furthermore, multiplex studies can increase the sensitivity and specificity of
disease diagnostics, and thus result in fewer false positives and false negatives as compared
to single markers [67].
The miniaturized design of these antibody microarrays (<1 cm2) is based on the
immobilization of minute amounts of antibodies (~ 400 pL) onto a solid support in an
ordered pattern, a microarray (Figure 1.1.) [18]. These antibodies serve to bind protein
analytes onto the surface. The microarrays are incubated with small amounts of sample (~
20 μL) and then generally tagged for fluorescent detection. An enzyme-dependent signal
amplification step, such as biotin tyramide, is often used to reach sensitivities in the fM
range, and allow for the detection of low-abundant (pg/ml) protein analytes [18] [51] [68]
[69].
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Figure 1.1. Schematic diagram of sandwich ELISA microarray. Antibody microarrays are
often performed based on two distinct experimental constructs: label-based assays or
sandwich assays [67]. Label-based assays rely on the capture of tagged protein analytes for
detection. This format allows the co-incubation of different tagged protein analytes. Coincubation makes analytes compete for binding. Competitive assays have some advantages
over non-competitive assays in terms of linearity of response and dynamic range [70]
Sandwich assays rely on the presence of a second ‘detection’ antibody that binds to the
same antigen as the immobilized ‘capture’ antibody, but with affinity for a different site
(Figure 1.2.). This detection antibody is typically biotinylated for subsequent measured
using streptavidin labeled with a fluorophore or enzyme [13]. The use of matched antibody
pairs to target each antigen increases assay sensitivity and specificity [45]. Sandwich
assays are non-competitive as they permit the incubation of only one sample. Noncompetitive assays have sigmoidal binding responses of narrower dynamic ranges [67].
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Figure 1.2. Schematic demonstrating the difference between labeled based assays and
sandwich based assays.
1.2.2. Specificity and Cross-Reactivity
Sensitivity refers to the percentage of individuals with a disease who test positive for a
marker in question, while specificity refers to the percentage of individuals without disease
who test negative for the same marker [8]. The lower the sensitivity, the more often
individuals with the disease will pass undetected, and the lower the specificity, the more
often individuals without the disease will test positive [71]. A major challenge in the
validation of cancer biomarkers is high variability and low incidence of specific cancers
across populations [45]. As a result, assays of very high sensitivity and specificity are
required. Otherwise, biomarkers are unable to distinguish individuals both with and
without the disease [45]. A number of potential biomarkers do not progress beyond this
point for this very reason [60]. Similarly, even many of the best biomarkers presently
available, often fall short in meeting those expectations, as is the case with prostate specific
antigen (PSA). As a biomarker for prostrate cancer PSA exhibits sensitivities greater than
90%, however has specificities of only 25%. This high incidence of false positives results in
a large number of unnecessary and often invasive biopsies that take a toll in the lives of
8

people that extends far the financial one [72] [73] [74] [75]. In a similar manner, the
biomarker for breast cancer CA15.3 only reaches sensitivities of 23% and specificities of
69% and as a result is limited to monitoring advanced stage breast cancer responses to
treatment or recurrence [8]. The analysis of multiple protein profiles rather than reliance
on single biomarkers offer the potential to achieve the sensitivity and specificity that is
required the early detection [7].
Although sandwich assays are known for their high sensitive and specificity, in multiplex
studies great care needs to be taken in order to ensure no cross-reactivity or interference
exists. While often negligible in arrays of limited complexity, large-scale studies screening
libraries of antibodies against a number of potential targets increase the prevalence of
cross-reactive binding. Cross-reactivity often occurs due to sequence and/or structure
similarity of binding sites. Monoclonal antibodies tend to be more susceptible to crossreactions than polyclonal antibodies, for which effects are dissipated by the heterogeneity
of the antibody population [4]. In addition, non-specific interactions can render proteins
inactive, often just by making binding sites inaccessible through steric hindrance. Efforts to
further develop the microarray technology as a result are directed toward the reduction of
cross-reactivity between assays [76].
1.2.3 Surface and Attachment
One of the main challenges in the development of protein and antibody microarrays is the
immobilization of molecules of diverse structures and characteristics onto a solid support
in a manner that also maintains their innate binding properties. Surface chemistries and
immobilization procedures are crucial for the optimal performance of microarray
9

platforms, as is evident by the large number of slide surfaces commercially available [77].
Ideal surfaces for ELISA microarray need to provide not only strong attachment of the
immobilized antibodies, but also retain their inherent activity and display high binding
capacities, signal-to-noise ratios, and reproducibility across all chips, slides, and
experiments [78]. Additionally, the high-throughput nature of the platform requires
supports to be robust and retain high levels of specificity and sensitivity through rigorous
processing conditions and prolonged storage periods.
Globular proteins usually consist of a hydrophobic core and hydrophilic surface.
Immobilization onto hydrophobic surfaces destabilizes protein structure, in essence
turning its inside out, and as a result rendering it inactive [79]. Antibodies in particular
need to maintain their native confirmation upon immobilization in order to retain binding
specificity [80]. In addition, unlike DNA, which have a uniform negatively charged
phosphate backbone exterior that allows for its relatively facile immobilization onto
oppositely charged surfaces, protein surface charges are very diverse, and consequently
often require complex surface chemistries and immobilization procedures [77]. The
challenge lies in designing a microarray support that accommodates proteins of varying
characteristics in a way that provides a non-denaturing environment that preserves the
active form of the protein.
There are a number of immobilization strategies and solid supports currently in existence
[81] [82] [83] [84] [85] [86]. However, microarray surfaces can in general be broadly
categorized into two main types: two-dimensional surfaces and three-dimensional
surfaces. While two-dimensional surfaces allow for the direct attachment of proteins to the
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surface, three-dimensional surfaces retain proteins within a matrix (Figure 1.2.). Glass
slides are widely preferred as two-dimensional solid support platforms because of their
inherent low fluorescence [65] [87] [88] [89] [90] [91]. However, in order to facilitate
attachment, glass slides have been functionalized with a variety of different chemical
modifications. Two-dimensional surfaces include aldehyde [89] [92], aminosilane [77] [93]
[94], epoxysilane [93] [94], mercaptosilane [94], polystyrene [77], and poly-L-lysine coated
slides [65]. These surfaces immobilize proteins through electrostatic and covalent
interactions. Covalent attachment is often achieved through cross-linking, via amine or
thiol groups. While these surfaces offer a number of advantages, due predominantly to the
unique combination of both strong attachment and low coefficients of variation, they also
present distinct disadvantages, including, high rates of evaporation and close contact with
the surface, which can affect protein structure [24].

Figure 1.3. Schematic demonstrating the three-dimensional surfaces, two-dimensional
surfaces, and other more specialized microarray surfaces.
Three-dimensional surfaces include polyacrylamide [89] [95], agarose [90] and
nitrocellulose gels [96] [97] [98] [99] [100] [101], as well as poly(vinylidene fluoride)
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(PVDF) membranes [102] [103]. These surfaces immobilize proteins through physical
adsorption, retaining them within its structure via hydrophobic interactions. These
matrices provide a more protein friendly environment that preserves their native
conformation, allowing for a more optimal surface for binding, and hence higher binding
capacities and signal intensities [104]. However, while these surfaces perform well in terms
of limits of detection, as a whole, they display much higher coefficients of variation [77].
Background fluorescence can also be matter of concern, and surfaces often require much
more involved pretreatment and blocking procedures. Additionally, because of the more
complex nature of their three-dimensional structure, permeability can also considerably
complicate the kinetics of the protein interactions, due primarily to the slow rates of
protein diffusion [98].

Figure 1.4. Schematic representation poly-L-lysine coated microarray slides.
There exist other more specialized surface chemistries that are more difficult to categorize
as they combine characteristics of the two. While they do not provide a three-dimensional
structure within which proteins could be retained, these surfaces cannot be considered to
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be two-dimensional either as the do incorporate some sort of supra-molecular surface
assembly for attachment [24]. Surfaces which these characteristics include avidin [105],
streptavidin [84], nickel [92] dendrimer [106] [107], or polyethylene glycol (PEG) slides
[108]. These surfaces immobilize proteins through the covalent attachment of epoxy and
specialized affinity groups. Affinity binding improves coupling and lessens direct surface
contact destabilization. Avidin and streptavidin-coated surfaces are for these reasons
widely used for the immobilization of biotinylated capture molecules. In a similar manner,
histidine tags facilitate attachment on nickel-coated surfaces. Dendrimers increase the
density of functional surface groups to optimize protein immobilization. PEG layers prevent
direct surface contact and reduce background binding lessening the need of blocking
reagents.
High-throughput demands in protein microarrays require the selection and development of
optimized support surfaces that allow for more generally applicable and direct
immobilization procedures. While high binding affinities are imperative in preventing
antibody loss and ensuring surface attachment withstands processing conditions, which
involve rather extensive wash procedures. The reality of antibody immobilizations is that
functional loss can occur as a result of relatively passive interactions, as well as more
structurally intrusive chemical linkages. Angenendt et al. [77] compared the limits of
detection, coefficients of inter- and intra-chip variation, and storage characteristics for
different commercially available slide variations. While no particular slide took all areas, in
terms of overall array performance, poly-L-lysine and aldehyde slides displayed the best
signal uniformity and signal-to-noise ratios. Kusznezow et al. [94] studied a number of
variables affecting antibody microarrays, including surface modifications, cross-linking
13

strategies, spotting buffer compositions, blocking reagents, antibody concentrations, and
storage conditions. For surfaces where antibodies were not covalently attached, poly-Llysine slides displayed superior signal-to-noise ratios, despite having rather relative low
signal intensities. Nitrocellulose surfaces on the other hand exhibited the highest signal
intensities, however as with other three-dimensional surfaces, also produced high
background signals. For surfaces where antibodies were covalently attached, cross-linked
silane surfaces performed best, displaying good sensitivity and signal-to-noise ratios.
Evaluating similar surfaces, Servoss et al. [78] found that as a whole, three-dimensional
slide surfaces have higher background fluorescence than two-dimensional slide surfaces,
due predominantly to the increased difficulty these more complex surfaces present to
efficiently block and wash the surface. Additionally, no significant drop off was observed
when assessing antibodies immobilized on non-covalent surfaces as compared to those
attached covalently.
1.3. Poly-N-Substituted Glycines (Peptoids)
Inspired by natural polymers, the work of chemists and chemical engineers has focused in
the development of synthetic polymeric materials that are able to mimic some of the
fundamental molecular features that allow for the diverse array of functional structures
nature so elegantly creates with just a set of monomeric sequences and interactions [109].
Polypeptides confer proteins a myriad of unique functional properties, providing for
example, binding and catalytic sites that together hence enable molecular recognition.
However, as biocompatible materials peptides present a major drawback, they are
susceptible to in vivo proteolitic degradation, and as a result are limited in their potential
14

for biomedical and therapeutic applications [110]. Efforts to overcome these limitations
have led to the design and development of innovative peptidomimetic oligomers [111]
[112] [113] [114] [115] [116]. Synthetic polymer analogs exploit structural similarities in
order to allow for the mimicry of bioactive functionalities. These bioactive roles are often
determined by the unique ability of peptides to self-assemble into complex, sequencespecific three-dimensional secondary structures [117]. Specific peptidomimetic oligomers,
commonly referred to as foldamers [118], which in addition to the mimicry of primary
structure display well-defined secondary structures, are therefore of great interest.
Oligomeric N-substituted glycines (peptoids) are a form of bioinspired peptidomimetic
polymers whose backbone structure closely resembles that of peptides, but have side
chains appended to the amide groups rather than the α-carbons (Figure 1.5.). This
structural modification prevents proteolytic degradation, making peptoids a promising
alternative as biocompatible materials for therapeutic applications. However, this
modification also removes the presence of backbone amide hydrogens, critical for
secondary structure, at least in terms of allowing for the formation of the same type of
hydrogen bond linkages that stabilize beta sheets and helices in peptides. Despite these
limitations, secondary structures such as turns, loops, and helices that in turn allow for the
formation of supramolecular assemblies can be induced in peptoids upon the addition and
proper placement of specific side chains [119]. The inclusion of chiral aromatic side chains
has been demonstrated to incite the formation of helical secondary structures reminiscent
of polyproline type I helix [120], stabilized primarily through steric and electrostatic
interactions [117]. Circular dichroism (CD) spectra of these peptoids closely resemble the
spectra of peptide α-helices [121].
15

Figure 1.5. Structural comparison of peptide and peptoid molecules.
Like peptides, peptoids can be constructed via an automated, solid-phase synthesis [122].
The submonomer method provides a robust and highly efficient platform for synthesis,
enabling precise control over sequence functionality. Synthesis follows a carboxy to amino
direction, in which each cycle of monomer addition consists of a two-step process: (1)
acylation and (2) nucleophilic substitution (Figure 1.6.) [121]. Functional moieties are
introduced by the incorporation of commercially available primary amines, enabling access
to a wide variety of side chain chemistries (>100 monomers) [109]. High monomer
coupling efficiencies (98%) [123] additionally allow for the precise sequence-specific
synthesis of polymer chains surpassing over 300 monomeric subunits in length [124].
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Figure 1.6. Submononer synthesis on Rink-amide resin.
Peptiods allow for the precise spatial positioning of diverse chemical functionalities,
enabling the design of novel materials with distinct chemical properties. Peptoids are of
great interest as biomimetic materials for therapeutic applications because they display
low immunogenicity, are protease-resistant, biocompatible, and soluble in water. They are
attractive as polymeric materials as they offer a remarkable ease of assembly, sequence
programmability, and relatively low costs. In addition, they enable the incorporation of a
variety of highly customizable side chain chemistries, and allow for the precise control of
sequence and length specificity, as well as the formation of defined three-dimensional
conformational assemblies. Lastly, the mimicry of the natural proteins allows for the study
of fundamental sequence, structure, and function relationships, and hence potential
sighting in the understanding of the protein structure-function paradigm.
2. Research Rationale
While knowledge of different types of diseases and their progression has grown
remarkably in the last decades, the economic costs, extensiveness of treatment, and
mortality associated with many of these diseases continue to in large be hampered by our
ability to detect when therapeutic treatments present their greatest potential—before the
17

disease is widespread—the incipient stages of development. Thus, there is a critical need to
develop sensitive assays that can detect molecular changes associated with the onset of the
disease. Enzyme-linked immunosorbent assay (ELISA) microarray technology offers a
promising mean for the attainment of this goal. Surface chemistries and immobilization
procedures are crucial for the optimal performance of microarray platforms. The challenge
lies in the immobilization of capture molecules of diverse structures and characteristics
onto a solid support in a manner that allows for strong attachment, but also retains their
inherent activity. These assays need to display high reproducibility, binding capacities, and
signal-to-noise ratios. Additionally, the high-throughput nature of the platform requires
supports to be robust and retain high levels of specificity and sensitivity through rigorous
processing conditions and prolonged storage periods.

Figure 2.1. Representative schematic for the increased antibodies binding.
The comprehensive goal of this project is to develop a biocompatible surface coating that
increases the available surface area. The surface area difference between the microsphere
18

coated three-dimensional surface and the uncoated two-dimensional surface given the
average microsphere diameter of 1.59 um is of 157% assuming that antibody
immobilization occurs only in the projected top half of each microsphere. We hypothesize
that the proposed peptoid-based microsphere coatings will enhance the binding efficiency
of capture reagents, increasing the dynamic range and sensitivity of biosensor
technologies. Peptoids are bio-inspired sequence-specific polymers based on a polyglycine
backbone with side chains appended to the amide groups. Peptoids are attractive as
biocompatible materials for therapeutic applications because of their relative low costs,
ease of synthesis, highly customizable side-chain chemistry, biostability, biocompatibility,
and low cytotoxicity. The Servoss lab has demonstrated that helical peptoids with partial
water solubility self-assemble into microspheres.
The hypothesis will be confirmed by completing the following aims:
1. Compare the ELISA microarray performance of the peptoid microsphere-coated
slides with commercially available slides. We hypothesize that the increase in
surface area provided by the microsphere coatings will enhance the dynamic range and
sensitivity of assays performed in surfaces providing similar chemistries for
attachment. The proposed peptoid-based coating will be assessed in reference to glass
and poly-L-lysine coated surfaces in order to evaluate non-covalent and covalent
immobilization strategies. The binding efficacy of the peptoid microsphere-coated glass
substrates will be analyzed by ELISA microarray with known antibody assays.
2. Investigate the factors affecting microsphere morphology following deposition on
a solid surface. We hypothesize that the ionic properties of the solvent, including ionic
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strength, pH, and Hofmeister solubility, play a crucial role in determining the ultimate
stability of the microspheres. It is believed that pi-pi stacking of the chiral aromatic
groups along with hydrophobic effects lead to self-assembly of the peptoids into
microspheres. Preliminary robustness studies have demonstrated that the microsphere
coatings are able to withstand all processing conditions associated with ELISA
microarray, but prolonged exposure to water leads to degradation of the peptoid
microspheres. CD will be used in order to determine any effect on helicity, while SEM
will be used in order to study the robustness of the spheres in the diverse conditions.
3. Investigate the effect helicity plays on microsphere size formations. We
hypothesize that peptoid sequences exhibiting stronger helical secondary structure will
form smaller microspheres as compared to those peptoids exhibiting less structured
helices. Preliminary findings demonstrate that the inclusion of positively and negatively
charged groups in the third face of the helix formed microspheres nearly 10 times
smaller than those obtained with the sequence being currently used. It is believed that
these opposite charges interact to form tighter helices which result in the smaller
supramolecular assemblies observed [125]. CD studies will be performed in order to
quantify peptoid helicity, while SEM will be used for the visual assessment of
microsphere size.
3. Deposition of Uniform Peptoid Microspheres Coatings
3.1. Materials
Amine sub-monomers: 4-methoxybenzylamine and (S)-methylbenzylamine were
purchased from Acros Organics (Pittsburgh, PA). tert-butyl N-(4-aminobutyl)carbamate
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was purchased from CNH Technologies Inc. (Woburn, MA). MBHA rink amide resin was
purchased from NovaBiochem (Gibbstown, NJ). Piperidine was purchased from SigmaAldrich (St. Louis, MO). Test grade silicon wafers were purchased from University Wafer
(South Boston, MA). Poly-L-lysine and ultra clean glass microarray slides were purchased
from Thermo Scientific (Pittsburgh, PA). Disuccinimidyl suberate (DSS) and
bis[sulfosuccinimidyl] suberate (BS3) were purchased from Pierce (Rockford, IL, USA).
Purified antibodies and antigens were purchased from R&D Systems (Minneapolis, MN,
USA). Blocking solution containing 10 mg/ml casein in phosphate-buffered saline (PBS)
was purchased from Bio Rad Laboratories (Hercules, CA, USA). Tyramide Signal
Amplification (TSA) system, including streptavidin-conjugated horseradish peroxidase,
amplification diluent, and biotinyl tyramide, was purchased from Perkin Elmer (Wellesley,
MA, USA). All other reagents for synthesis, purification and sample preparation were
purchased from VWR (Radnor, PA). All chemicals were used without further modification
unless otherwise specified.
3.2. Methods
3.2.1 Peptoid Synthesis
Peptoids were synthesized via the submonomer solid-phase method on rink amide resin
[122]. The resin was initially swelled with dimethylformamide (DMF), and the Fmoc
protecting group on the resin was removed using a 20% solution of piperidine in DMF. The
resin-bound secondary amine was acylated with 0.4 M bromoacetic acid (BAA) in DMF, in
the presence of N,N’-diisopropyl carbodiimide (DIC), mixing for 1 minute. Amine sub-
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monomers were incorporated via an SN2 nucleophilic substitution reaction with 0.5M
primary amine in DMF, mixing for 2 minutes. The two-step bromoacetylation and
nucleophilic substitution cycle were repeated until all desired side chains has been
incorporated (Figure 3.1.). Once the synthesis was complete, the peptoid was cleaved from
the resin using a mixture of 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5%
triisopropylsilane (TIS), mixing for 5 minutes. The acid was removed using a Heidolph
Laborota 4001 rotating evaporator (Elk Grove Village, IL) and peptoids were diluted to a
concentration of ~3 mg/mL in a 50:50 acetonitrile-water solution.
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Figure 3.1. Peptoid structure for the P3 sequence.
3.2.2 Purification
Peptoids were purified using a Waters Delta 600 preparative high-performance liquid
chromatography (HPLC) instrument (Milford, MA) with a Duragel G C18 150 × 20 mm
column (Peeke Scientific, Novato, CA) using a linear gradient of 35-95% solvent B
(acetonitrile, 5% water, 0.1% TFA) in A (water, 5% acetonitrile, 0.1% TFA), over 60
minutes. Peptoids were confirmed to be >98% pure via analytical HPLC (Waters Alliance,
Milford, MA) with a Duragel G C18 150 × 2.1 mm column (Peeke Scientific, Novato, CA)
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using a linear gradient of 35 to 95% solvent D (acetonitrile, 0.1% TFA) in C (water, 0.1%
TFA), over 30 minutes. Purified peptoid fractions were lyophilized using a Labconco
lyophilizer (Kansas City, MO) and stored for use as a powder at -20 °C.
3.2.3 Characterization
Matrix Assisted Laser Desorption/ionization Time of Flight (MALDI-TOF). Proper
synthesis was confirmed via MALDI (Bruker, Billerica, MA) mass spectrometry. The mass
of the purified peptoid samples (Figure 3.2.) matches the expected theoretical molecular
weight (1917 Da).

Figure 3.2. MALDI-TOF spectrum of peptoid, MW: 1917 Da.
Circular dichroism (CD). Secondary structure was confirmed via CD spectrometry using a
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Jasco J-715 instrument (Easton, MD) at room temperature with a scanning speed of 20
nm/min and a path length of 0.1 mm. The spectra (Figure 3.3.) exhibits the characteristic
maxima near 190 nm and two minima near 205 and 220 nm commonly associated to
polyproline type I helices [121]. The peptoid was dissolved in methanol at a concentration
of 120 µM because protic solvents have been demonstrated to help induce helical
secondary structure in peptoids. Each spectrum was the average of twenty accumulations.
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Figure 3.3. Circular dichroism spectra of peptoid showing a poly-proline type-1-like helical
secondary structure. CD spectra were taken at room temperature with a scanning speed of
20 nm/min and a path length of 0.1 mm. The peptoid was dissolved in methanol at a
concentration of 120 µM.
3.2.4. Microsphere Formation
Peptoid microspheres were prepared by dissolving the peptoid in a 4:1 (v/v) solution of
various organic solvents/water at a range of concentrations. The peptoid solutions were
deposited onto various surfaces of approximately 1 cm × 1 cm using a pipette under a
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variety of different conditions.
3.3.5 Morphology Studies
Scanning electron microscopy (SEM). Peptoid microsphere coating morphologies were
visually assessed at the Material Characterization Facility using a Phillips XL-30
environmental SEM (FEI, Hillsboro, OR) in order to determine effect of a number of
optimization conditions on both the ability to form uniform self-assembling peptoid
microsphere and consequent coatings with the latter.
3.3. Peptoid Microspheres Coatings
3.3.1. Peptoid Microspheres
Previous work in our lab has shown that helical peptoids that are in addition partially
soluble in water are able to self-assemble into microspheres. Helicity in the structure is
sterically induced with the inclusion of chiral aromatic side chains in two of the three faces
of the helix (Figure 3.1.). Because these microspheres (∼2 μm) (Figure 3.4.) are orders of
magnitude larger than the single peptoid helix (∼24 Å), we have proposed that the stacking
of the chiral aromatic groups allow for formation of larger peptoid groupings that coupled
to hydrophobic effects self-assemble into microspheres (Figure 3.5.) [125]. Similar types of
supra-molecular assemblies have been observed by this sort of aromatic stacking in both
peptides and peptoids [126] [127] [128] [129] [130].
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Figure 3.4. SEM image of peptoid microsphere.

Figure 3.5. Schematic Representation of peptoid microsphere formation [146].
Past work in our lab has focused in the analysis of various parameters (i.e. partial water
solubility, helical content, charge placement, and side chain bulk) affecting the selfassembly peptoids microspheres [125], and to an extent even the reproducible formation
of these microspheres on silica surfaces [131]. Focus now continues on to the controlled
deposition of robust uniform petoid microsphere coatings on glass slides. The peptoid
sequence that has been selected for this work is based on these prior studies. SEM studies
reveal that the administration technique by which the peptoid solution is applied to a
surface greatly affected the uniformity of the coating and suggest that the horizontal full
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coverage, as compared to some of the more readily utilized high throughput alternatives,
such as dip coating, was necessary for best results. In order to ensure reproducibility of
results, fixed peptoid volumes were administered with a pipette, covering the entire
surface outlined by 1 cm × 1 cm delimiting wax imprints. It has been shown that protic
solvents aid in stabilizing helical secondary structure in peptoids through hydrogen
bonding [117] [132] [133] [134]. Solvent choice was investigated with the use of three
different protic solvents (i) methanol, (ii) isopropanol, and (iii) ethanol (Figure 3.6.).
Peptoids were dissolved in 4:1 organic solvent/water solution. While SEM images reveal
sphere-like assemblies for all solvents, the most uniform spheres are formed with the use
of ethanol as the protic solvent choice.

Figure 3.6. SEM images demonstrating the effect of different protic solvents on sphere
formation: A) methanol, B) isopropanol, and C) ethanol.
3.3.2. Microsphere Coatings
The effect of drying conditions was similarly investigated by varying the humidity at which
the peptoid solution was allowed to evaporate. For this analysis, the peptoid solutions were
dried at (i) high humidity (85%) in a humid chamber (~120 minutes), (ii) open air (~30
minutes), and (iii) vacuum chamber (~5 minutes). Drying conditions greatly affected the
uniformity of the spheres and coating deposition on the surface. Whether it was the
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formation of sparse clusters of non-uniform globular aggregates at vacuum or clumped
spheres at high-density regions towards the perimeter and center of the coverage area at a
high humidity. Open air-drying, although with its own detriments (i.e. still perimetral
intensive and sparse in the inner region) from a coverage standpoint, consistently formed
the most uniform microspheres and surface coverage (Figure 3.7.).

Figure 3.7. SEM images demonstrating the microsphere coatings coverage difference at the
perimeter and center.
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Figure 3.8. Schematic representation of the coverage uniformity improvement upon
addition of tween surfactant.

Figure 3.9. Microsphere coating coverage with optimized conditions at 3 different
magnifications.
Coating morphology is directly linked to the mode of evaporation. In droplets, it is known
that at atmospheric pressure, two main modes of evaporation occur: first, droplets flatten
with a constant contact area, to then shrink at a constant contact angle. A constant contact
area mode of evaporation is desired in order to obtain uniform coating depositions. In
addition, perimetral intensive depositions are often indicative of preferential substrate
accumulations at the air/liquid interface. The addition of surfactants can be used to
preserve a constant contact area mode of evaporation by decreasing droplet surface
tension, lowering the contact angle, and in turn improving the stability of the droplet by
reducing the pullback forces at the perimeter during evaporation. In addition, surfactants
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can be competitively used to displace substrates at the air/liquid interface, and thus lessen
the perimetral deposition on the surface (Figure 3.8.). Results for the addition of Tween
surfactant show considerable improvements on the overall uniformity of the coating,
lessening perimetral microsphere deposition and allowing for an even distribution of
microspheres throughout the entire surface (Figure 3.9.). At higher concentrations (>
0.1%) Tween addition clumped adjacent microspheres to each other, and when added to
the solvent prior to the peptoid affected size uniformity in microsphere formation.
In order to increase the inner region coverage, peptoid concentrations and volumes for
coverage where optimized. It was possible to increase peptoid concentrations from 3
mg/mL to 5 mg/mL to increase microsphere coverage density without disrupting the
morphology and uniformity of either the spheres or coating (Figure 3.10.). Decreases in
volume of peptoid solution added greatly affected the coverage density (Figure 3.11.),
while increases in volume only further increased the deposition of microspheres towards
the perimeter with minimal inner region improvement.

Figure 3.10. SEM images demonstrating the difference in microsphere coverage with
peptoid concentration: A) 3 mg/ml, B) 4 mg/ml, and C) 5 mg/ml.
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Figure 3.11. SEM images demonstrating the difference in microsphere coverage with
volumes: A) 15 ul, B) 30 ul, and C) 45 ul.
ImageJ analysis of the microsphere coatings demonstrate 83.5 ± 3.4 % surface coverage at
optimized conditions. Although the peptoid microsph ere coating has similar reactive
moieties to poly-L-lysine, the contact angle of the peptoid microsphere coating is
considerably more hydrophobic than the poly-L-lysine slides, 53.2 ± 3.9 degrees versus
30.3 ± 2.4 degrees. In general, hydrophobic surfaces limited solvent spreading. The
increased roughness of the peptoid microsphere coatings as compared to two dimensional
surfaces would similarly disrupt solvent spreading.
4. Detection and Validation of Cancer Biomarkers
4.1 Introduction
Protein microarrays are recognized as one of the most valuable tools in proteomics.
In protein microarrays, proteins are immobilized on a solid substrate for the efficient and
high-throughput parallel analysis of large population profiles. The technology offers a wide
range of applications, including expression profiling, interaction profiling, and functional
identification [135]. Protein concentration profiles may depend on age, physicochemical
characteristics of the environment, and among those of interest, disease state. The need to
study beyond mRNA profiling arises due to post translational modifications and general
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protein degradation by proteolysis. Protein screening thus offers a direct way to phenotype
cells and diagnose disease state, stage, and response to treatment [135]. This approach has
been successfully explored with antibody arrays, where microarray protein chips based on
immunological antibody/antigen interaction, offer the necessary high specificity and
sensitivity, that have allowed for the development of the broad applications in the
technology: proteome analysis, disease diagnostics, identification of biomarkers, and
pharmaceuticals response profiling [136] [137].
Among several available immunoassays, ELISA is a popular because of its high
specificity, sensitivity, and high throughput [13]. In ELISA, capture antibodies are first
immobilized onto a solid support. Those capture antibodies then bind to specific antigen.
The chip is then incubated with a detection antibody that binds to the same antigen as the
capture antibody, but does so at a different site. Finally, the detection antibodies are tagged
with a fluorescent dye, before the slide is scanned for a fluorescent signal with a laser
scanner. The intensity of the fluorescence signal is directly related to the concentration of
the substrate, and thus allow for the quantitative application of results.
4.2 Materials
Poly-L-lysine and ultra clean glass microarray slides were purchased from Thermo
Scientific (Pittsburgh, PA). Disuccinimidyl suberate (DSS) was purchased from Pierce
(Rockford, IL, USA). Purified antibodies and antigens were purchased from R&D Systems
(Minneapolis, MN, USA). Additional antibodies and glycans were provided by our
collaborators at Detroit R&D. Blocking solution containing 10 mg/ml casein in phosphatebuffered saline, pH 7.2 (PBS) was purchased from Bio Rad Laboratories (Hercules, CA,
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USA). Tyramide Signal Amplification (TSA) system, including streptavidin-conjugated
horseradish peroxidase, amplification diluent, and biotinyl tyramide, was purchased from
Perkin Elmer (Wellesley, MA, USA). Alexa647-conjugated streptavidin was purchased from
Invitrogen Life Technologies (Gaithersburg, MD). All other reagents were purchased from
VWR (Radnor, PA). All chemicals were used without further modifications unless otherwise
specified.
4.3. Methods
4.3.1 Microarray Printing
ELISA microarray spotting was performed at room temperature and 60% relative humidity
as previously described [138]. A GeSiM NanoPlotter 2.1 (Quantum Analytics, Foster City,
CA, USA) non-contact microarray printer with humidity control was utilized to spot the
proteins. In some cases, proteins were covalently boud t the slides with a 0.3 mg/ml
solution of the homo-bifunctional cross-linker DSS mathanol for 20 minutes. Prior to
spotting, the slides were rinsed in nanopure water and dried in a centrifuge. Capture
antibodies were suspended in PBS to a concentration of 0.5-1.0 mg/ml and ~400 picoliters
per spot were printed at various different layouts. The antibodies were allowed to dry for
an additional hour at 60% relative humidity. The slides were blocked with 10 mg/ml casein
in PBS, rinsed in nanopure water and dried in a centrifuge. Upon completion, the slides
were either stored under vacuum for future use at -20 °C or shipped to our collaborators.
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4.3.2 ELISA Microarray
ELISA Microarray was performed as previously described [138], with all incubation steps
performed at room temperature, in a closed humid chamber with gentle mixing on an
orbital shaker (Belly Dancer, Stovall Life Science, Greensboro, NC). A two-step wash
procedure between processing steps was performed by submerging the slides twice into
PBS containing 0.05% Tween-20 (PBS-T). The slides were incubated with different antigen
standards in 1 mg/ml casein in PBS overnight. Standard curves were created using a fivefold dilution series of the antigen mix along with an antigen-free blank for 8 total dilutions.
Following a wash cycle, the slides were incubated with biotinylated detection antibody at
25 ng/ml in 1 mg/ml casein in PBS. The signal was amplified using the TSA system
following manufacturer instructions, and incubated with 1 μg/ml Alexa647-conjugated
streptavidin in PBS-T. Prior to scanning, the slides were rinsed twice in PBS-T and in
deionized. A GenePix Autoloader 4200AL (Molecular Devices, CA) laser scanner was used
to image the Alexa 647 fluorescence signal on the slides. The spot fluorescence intensity
from the scanned slide images was quantified using GenePix Pro 3.0 software. Standard
curves were created using ProMAT, a software program specifically developed for the
analysis of ELISA microarray data [139].
4.4. ELISA Microarray Marker Assays
4.4.1. Antibody Assays
Initial research was conducted for the development of standard curves on 26 different
ELISA microarray antibody assays. Large studies insert greater indices of variation that are
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reflected on the quality of standard curves that can be developed. For this reason,
significant work was conducted on further optimizing standard curves of all antibodies. In
order to do so, special focus was placed on the development of a new antigen mix for the
development of the standard curves. The optimized antigen concentration can be seen in
Table 1. EGF, GFP, and PSA antigens were excluded from the antigen mix and prepared as
separate independent stock solutions from which to be added fresh for each experiment.
Additionally, we developed a homemade biotinyltryramide and amplification diluent.
These solutions were compared to the TSA amplification kit solutions, obtaining very
favorable results with comparable quality. In order to prevent any undesired interactions
that might compromise assay specificity and sensitivity, cross-activity studies were first
performed on all antibodies. Cross-reactivity studies involve a series careful evaluations
[66]. In short, individual antigen and detection antibody pairs are first tested on arrays
containing all capture antibodies. Undesired interactions would be detected upon
evaluation of signal intensities, no cross-reactivity of either the antigen or the detection
antibody with any capture antibody was detected. Nonspecific antigen contamination is
then similarly assessed, however this time with all antigens present. A final round of
screenings is conducted. These screens consist in preparing separate antigen mixes by
removing one of the antigens from the mix, and screening each mix independently using a
mixture with all detection antibodies, and then doing the opposite, preparing separate
detection antibody mixes, and screening each mix independently using all mixture with all
antigens. Cross-reactivity was detected between the TGFalpha and FGFb antibodies. FGFb
was removed from future studies for this reason.
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4.4.2. Sample Screenings
Serum sample from cancer patients were screened to validate the potential markers. For
the initial 9-sample analysis, microarray slides with a 10x12 array layout containing all 26
different antibodies in quadruplicate were first spotted (Table 4.1.). For analysis, three
different dilutions of each serum sample in triplicate were utilized. Antigen concentrations
can vary by as much as 3 orders of magnitude [66]; for this reason samples are commonly
screened at three different dilutions (10-fold, 100-fold, and 1000-fold). The samples were,
in addition, arranged at random in order to prevent result bias associated with the
placement and processing of samples. Using this ELISA platform, we were able to detect 13
different antigens in the patient samples (CD14, EGF, EGFR, Eselectin, GDF-15, HBEGF,
Her2, ICAM, IL18, MMP1, PDGF-AA, PSA, and RANTES), as the other were below detection
limits (Amr, FGFb, HGF, IGF, IL1alpha, MMP2, MMP9, TGFalpha, TGFb, TNFalpha, uPAR, and
VEGF).
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Table 4.1. Summary of the results detailing the maximal concentration for all antigens.
Antigen

Max. Conc.

Antigen

Max. Conc.

Amr

2000

IL18

1000

CD14

5000

IL1alpha

500

EGF

500

MMP1

5000

EGFR

2500

MMP2

5000

Eselectin

2500

MMP9

2000

FGFb

5000

PDGF-AA

1000

GDF-15

250

PSA

5000

GFP

100

RANTES

500

HBEGF

500

TGFalpha

500

Her2

5000

TGF-b

5000

HGF

1000

TNF-alpha

500

ICAM

10000

uPAR

5000

IGF

2000

VEGF

750

The next major undertaking was proceeding with an 82-sample analysis that expanded on
the previous study. For this analysis, only two different dilutions (10 and 100-fold) of each
serum sample in triplicates were used. The analysis was conducted in 3 replicate batches in
random ordering as before. Each batch was conducted using 17 slides, with 3 standard
curves present for each. The data was calibrated to the GFP spot using ProMAT in an effort
to account for any spot, slide, location, and/or batch variations. All standard curves and
predicted concentrations along with data detailing information for each particular sample
as it relates to each antibody and batch, as well as a comparison for averaged block
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intensities for A647 and GFP on uncalibrated data to allow for an analysis on block to block
variations were sent to Detroit R&D. In general, results for the analysis demonstrated
similar trends, with CD14, EGF, EGFR, GDF-15, ICAM, PDGF-AA, and RANTES displaying
best results.
4.4.3. Glycan Prints.
Throughout this time, microarray slides most often with the 10x12 array layout containing
the 25 different antibodies in quadruplicate were constantly spotted and shipped to our
collaborators for further processing. Once the sample analysis concluded, work focused on
the printing of different markers of interest, in particular glycans. Glycan microarray slides
with a 6x6 array layout containing all 5 different glycans were spotted at a concentration of
0.5 mg/mL in quadruplicate for each block. In order to proceed with the spotting of the
glycans, the poly-l-lysine slides were first activated with the DSS. Although full analysis
was not performed on the slides, as they were shipped immediately upon printing to
Detroit R&D, the quality of the spotting was confirmed with the scanner using the red
reflect setting on the microarray scanner. Another frequent glycan print involved a 12x12
array containing 25 different glycans at a concentration of 0.5 mg/mL and 6 different
antibody standards at concentrations of of 1000, 100, 10, 1 ug/mL in 0.5 ug/mL BSA in
PBS. The print was conducted in quadruplicate for each block for a total of 16 blocks per
slide in DSS activated poly-l-lysine slides. Similarly, larger 38x8 arrays containing 74
different antibodies at two different concentrations (0.5 and 0.05mg/ml) in quadruplicate
for each block for a total of 4 blocks per slide were spotted and sent to Detroit R&D for
analysis.
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5. Identification of Tear Cancer Biomarkers
5.1 Introduction
Clinical applications remain limited by the need for more sensitive and reliable
methodologies for detection [140]. Tears fluids offer non-invasive insight into a complex
biological environment providing valuable information that might help reveal associations
between proteins and disease states. Proteomic technologies have currently identified
close to 500 different tear proteins [141] [142]. In this study, we develop a ELISA
microarray platform for the identification of tear proteins as potential biomarkers for
breast cancer.
5.2 Materials
Poly-L-lysine and ultra clean glass microarray slides were purchased from Thermo
Scientific (Pittsburgh, PA). Disuccinimidyl suberate (DSS) was purchased from Pierce
(Rockford, IL, USA). Purified antibodies and antigens were purchased from R&D Systems
(Minneapolis, MN, USA). Proteins were provided by our collaborators at Ascendant Dx.
Blocking solution containing 10 mg/ml casein in phosphate-buffered saline, pH 7.2 (PBS)
was purchased from Bio Rad Laboratories (Hercules, CA, USA). Tyramide Signal
Amplification (TSA) system, including streptavidin-conjugated horseradish peroxidase,
amplification diluent, and biotinyl tyramide, was purchased from Perkin Elmer (Wellesley,
MA, USA). Alexa647-conjugated streptavidin was purchased from Invitrogen Life
Technologies (Gaithersburg, MD). All other reagents were purchased from VWR (Radnor,
PA). All chemicals were used without further modifications unless otherwise specified.
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5.3. Methods
5.3.1 Microarray Printing
ELISA microarray spotting was performed at room temperature and 60% relative humidity
as previously described [138]. A GeSiM NanoPlotter 2.1 (Quantum Analytics, Foster City,
CA, USA) non-contact microarray printer with humidity control was utilized to spot the
proteins. In some cases, proteins were covalently boud t the slides with a 0.3 mg/ml
solution of the homo-bifunctional cross-linker DSS mathanol for 20 minutes. Prior to
spotting, the slides were rinsed in nanopure water and dried in a centrifuge. Capture
antibodies were suspended in PBS to a concentration of 0.5-1.0 mg/ml and ~400 picoliters
per spot were printed at various different layouts. The antibodies were allowed to dry for
an additional hour at 60% relative humidity. The slides were blocked with 10 mg/ml casein
in PBS, rinsed in nanopure water and dried in a centrifuge. Upon completion, the slides
were either stored under vacuum for future use at -20 °C or shipped to our collaborators.
5.3.2 ELISA Microarray
ELISA Microarray was performed as previously described [138], with all incubation steps
performed at room temperature, in a closed humid chamber with gentle mixing on an
orbital shaker (Belly Dancer, Stovall Life Science, Greensboro, NC). A two-step wash
procedure between processing steps was performed by submerging the slides twice into
PBS containing 0.05% Tween-20 (PBS-T). The slides were incubated with different antigen
standards in 1 mg/ml casein in PBS overnight. Standard curves were created using a fivefold dilution series of the antigen mix along with an antigen-free blank for 8 total dilutions.
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Following a wash cycle, the slides were incubated with biotinylated detection antibody at
25 ng/ml in 1 mg/ml casein in PBS. The signal was amplified using the TSA system
following manufacturer instructions, and incubated with 1 μg/ml Alexa647-conjugated
streptavidin in PBS-T. Prior to scanning, the slides were rinsed twice in PBS-T and in
deionized. A GenePix Autoloader 4200AL (Molecular Devices, CA) laser scanner was used
to image the Alexa 647 fluorescence signal on the slides. The spot fluorescence intensity
from the scanned slide images was quantified using GenePix Pro 3.0 software. Standard
curves were created using ProMAT, a software program specifically developed for the
analysis of ELISA microarray data [139].
5.4. ELISA Microarray Platform for the Identification of Cancer Biomarkers in Tear
Samples
Tear samples were collected from inside the lower eyelid using Schirmer strips, and
subsequently reconstituted in PBS for future use. Reverse-phase high-pressure liquid
chromatograph was used to fractionate tear proteins for identification. A linear gradient of
20%-30% solvent B (acetonitrile, 5% water, 0.1% TFA) in A (water, 5% acetonitrile, 0.1%
TFA) over the first 10 minutes, followed by 30%-70% solvent B in A gradient over the next
60 minutes, and a 70%-90% solvent B in A gradient over the last 10 minutes was used for a
total of 80 minutes [143]. Collected proteins were analyzed via electrospray ionization
mass spectrometry (ESI-MS).
Preliminary studies with our collaborators at Ascendant Dx helped identify 7 main tears
proteins of interest as potential biomarkers for breast cancer. In order to detect and
validate these proteins as potential biomarkers, a sandwich ELISA microarray based
41

platform was developed. Microarray ELISA allows for the parallel screening of multiple
proteins (refer to section 1.2.2 for additional details). However, in multiplexed studies
there exists the potential for proteins from different assays to interfere with each other.
This can happen via direct interactions between capture and detection antibodies, as well
as antibodies nonspecifically binding to another antigen or antigens present. In order to
prevent any undesired interactions that might compromise assay specificity and sensitivity,
cross-activity studies were first performed on all 7 antibodies. No cross-reactivity was
detected by the screenings. Standard curves were developed in order to ensure accurate
quantification of tear samples (Figure 5.1.). Of the 7 proteins analyzed, 4 proteins were
successfully detected in the human tear samples.

Figure 5.1. Standard curves for representative tear protein assay. Data is representative of
the other antibody assays.
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6. Biocompatible Interfaces for Neural Differentiation
6.1. Introduction
The use of stem cell regenerative medicine depends on understanding the complex,
dynamic interactions that occur in the extracellular matrix (ECM). While differences in the
mechanical and chemical interfacial properties of this environment have shown promising
effects on diverse cellular functions, the underlying role matrix interfacial properties play
on stem cell differentiation is yet to be fully understood. Efforts to mimic the extracellular
matrix via surface modifications are an attractive approach to understand the mechanisms
by which stem cells respond to inherent interfacial cues that affect cellular behavior.
Herein, we report the development of synthetic biocompatible interfaces that allow for the
tuning of chemical and mechanical properties of the matrix.
The devastating effects that are commonly associated with traumatic brain injuries and
degenerative diseases stem from limited regenerative capabilities of the central nervous
system (CNS). Among current tissue engineering strategies, stem cell-based regenerative
approaches have demonstrated promising results [144]. Neural stem cells (NSCs) are a
self-renewing and multipotent cells that can differentiate into neurons and glia, composed
mainly of, astrocytes and oligodendrocytes [145]. The differentiation of NSCs into neurons
is crucial for regenerative purposes. Stem cell differentiation is regulated by a combination
of complex intrinsic and extrinsic interactions. Intrinsic factors are dependent on cell
expression, while extrinsic factors are dependent on environment cues [146]. For this
reason, a number of different scaffolds have been studied in an attempt to develop a
cellular environment that allows for the selective differentiation of NSCs [147] [148] [149]
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[150] [151] [152].
Engineering this artificial extracellular matrices (aECM) allow to elucidate the proud
influence a cell’s environment has on its progression. These studies, offer valuable
mechanistic insights into the complex interactions that occur in the cellular environment. A
scaffold’s stiffness, for example, elicits different responses. Neural stem cells reach maximal
differentiation at a stiffness similar to that of the brain (500 Pascal) [153]. In general, softer
substrates tend to preferentially differentiate into neurons, while stiffer substrates tend to
preferentially differentiate into glial cells [151]. Studies also demonstrate that
topographical cues in the nanometer range elicit different responses, be that in roughness
[154] or geometry [155]. Cell behavior can also be influence by the presence of different
growth factors [156]. Three-dimensional scaffolds appear to similarly better mimic the
physiological environment that two-dimensional variants [157] [158].
6.2. Peptoid Microspheres Interfaces
Initial research was conducted in order to assess the viability of using peptoid based
microspheres in the development of an artificial extracellular matrix (aECM) that can be
tailored to promote the differentiation of stem cells into neurons. Peptoid microspheres
were prepared under sterile conditions. All laboratory equipment and materials were
sterilized using a 70% ethanol solution and/or autoclaved. While the microsphere coated
slides cannot be sterilized via the same ethanol based sterilization technique as they are
formed in a very similar solvents composition, and thus dissolve the peptoid coatings from
the surface, different sterilization techniques, such as UV-sterilization and ethylene oxide
gas sterilization, have proven to be viable alternatives. Peptoid microspheres were
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prepared by dissolving the peptoid in 4:1 (or 80%) ethanol to water solution at a
concentration of 3 mg/ml. The addition of 0.01% Tween-20 surfactant onto the peptoid
solution improves the overall uniformity of the coatings, allowing for an even distribution
of microspheres throughout the entire surface. The peptoid solution was applied to the
back (un-etched) face of the coverslips and allowed to dry for 30 minutes in a contained
environment under controlled conditions (i.e., 25 °C and 60% humidity). Three different
coating densities were prepared by varying the amount of peptoid solution added to each
coverslip. This approach has given us in the past control over the coating coverage. A 1X
concentration corresponds to 30 uL of the peptoid solution being added onto the surface. A
2X concentration corresponds to a second 30 uL addition of the peptoid solution being
added onto the existing 1X microsphere coverage, in essence doubling the concentration.
Similarly, a 3X concentration corresponds to a third 30 uL addition of the peptoid solution
being added onto the existing 2X microsphere coverage, tripling concentration. The coating
morphologies were visually assessed using a 3D Laser Scanning Microscope (Figure 6.1.).
SEM images require gold sputtering, and thus, are not a viable imaging technique to assess
the morphology of the coatings. The coverslips were prepared for shipped with the help of
Josh Goss from Dr. Zou’s research group at the University of Arkansas following the exact
specification used in the past. In short, the peptoid-coated 12mm cover slips were mounted
onto the back of 35mm petri dishes drilled with 9mm holes, sterilized previously via 70%
ethanol and plasma treatment, using PDMS. The peptoid cmicropher coated coverslips
were sent to Dr. Michael Borrelli’s research group for neuronal studies at the University of
Arkansas for Medical Sciences as part of the EPSCoR project.
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Figure 6.1. 3D laser scanning microscope images of the peptoid-based microsphere coated
cover slips for all three concentrations: 1X, 2X, and 3X.
6.3. Nano-Onion Interfaces
In the field of tissue engineering, graphene-based nano-materials, as are nano-onions, have
gained interest as biocompatible scaffold due to their unique physical, mechanical, and
chemical properties [159]. Carbon nano-onions are multi-shell fullerenes that resemble the
structure of onion, hence the origin of their name [160]. Graphene-based nano-materials
have been demonstrated to induce stem cell differentiation in neural lineages [161]. They
are attractive for neural tissue regeneration because they can incorporate extraordinary
topographical, thermal, and electrical properties to scaffolds [162]. They have been
demonstrated to be biocompatible and of low cytotoxicity materials [163]. In addition, they
can be chemically modified to enable the incorporation of diverse functional features [164].
Nano-onion nano-patterned coverslips were developed in order to asses where their
surface incorporation can regulate NSC differentiation. Nano-onion patterned slides were
similarly prepared under sterile conditions. Morphology of the patterns was evaluated via
SEM. The non-contact nanoplotter was used to spot different patterns across the glass
coverslips. The nano-onions dispersions were prepared by dissolving the nano-onions
nanoparticles at a 1 mg/mL concentration in a optimized solvent, which consists of a 1%
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BSA w/w, 0.05% Tween-20 surfactant v/v, and 5% glycerol v/v nano-pure water solution.
The nano-onions were initially were thoroughly mixed using a vortexer and then further
dispersed using a probe sonicator, and printed immediately using the non-contact nanoplotter Once the printing was complete, the coverslips were allowed to dry at standard
conditions (25 C and ~50% humidity) for 24 hours. Results with the optimized conditions
considerably improved nano-onion solvent dispersion and deposition uniformity (Figure
6.2.). The addition of glycerol was particularly beneficial when patterning lines over the
surface. However, overall spot patterns produced the most uniformly reproducible
patterns. In addition, they greatly decrease spotting times considerably. Higher nano-onion
concentrations made solvent pick up difficult for the nano-plotter. Based on previous work
a higher glycerol content would similarly difficult spotting for the nano-plotter as the
solution turns too viscous. The addition of 0.05% Tween-20 surfactant onto the nano-onion
solution improves both nano-onion dispersion and the uniformity of the patterns, allowing
for an even distribution of nano-onion patterned solutions on the surface. Higher
surfactant spread too much and affect reproducibility, in particular when patterning lines
instead of spots. Spot patterns with 5 mm margins on 22 x 22 mm on glass coverslips for a
patterned coverage of 12 x 12 mm were printed for Dr. Robert Griffin’s research group for
neuronal studies at the University of Arkansas for Medical Sciences as part of the EPSCoR
project.
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Figure 6.2. SEM images demonstrating the effect of optimized solvent on nano-onion
depositions at different magnifications A) line pattern at 1% BSA in water, and B) spot
pattern at 1% BSA, 0.05% Tween-20 surfactant in water.
7. Peptoid Microsphere Coatings to Increase the Binding Efficiency in Sandwich
ELISA Microarrays
7.1. Introduction
Over the last several decades there has been an enormous effort to develop sensitive,
disease-specific assays to assist in therapeutic decisions [1]. Early disease detection
decreases economic costs, improves treatment options, and reduces mortality [6].
Biomarker-based technologies, including ELISA microarray and bead-based immunoassay,
offer promising platforms for sensitive and specific disease detection [4]. Enzyme-linked
immunosorbent assay (ELISA) microarray technology has emerged as a strong platform for
the analysis of biomarkers [45] due to its ability to quantify low-abundance proteins in
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complex biological fluids over large concentration ranges [65]. The unmatched sensitivity
and specificity is associated primarily with the use of matched high-affinity antibody pairs
to target a single antigen. The miniature scale of the platform allows for cost-effective and
efficient parallel screening of small sample volumes in a high-throughput manner [45].
One of the main challenges in the development of ELISA microarray is the immobilization
of antibodies onto a solid support in a manner that maintains their innate binding
properties [24]. The surface chemistry of the solid support and the immobilization
procedure are crucial for optimal performance of microarray platforms, as is evident by the
large number of slide surfaces commercially available [77] [81] [82] [83] [84] [85] [86].
Surfaces for ELISA microarray need to provide strong attachment of the immobilized
antibodies while retaining binding activity, high binding capacities, high signal-to-noise
ratios, and high reproducibility across all blocks, slides, and experiments. Additionally, the
high-throughput nature of the platform requires supports to be robust and retain high
levels of specificity and sensitivity through rigorous processing conditions and prolonged
storage periods.
Although there are a number of immobilization strategies and solid supports available,
microarray surfaces can be broadly categorized as (1) two-dimensional surfaces and (2)
three-dimensional surfaces. While two-dimensional surfaces allow for the direct
attachment of proteins to the surface (aldehyde [89] [92], aminosilane [77] [93] [94],
epoxysilane [93] [94], mercaptosilane [94], polystyrene [77], and poly-L-lysine coated
slides [65]), three-dimensional surfaces retain proteins within a matrix (polyacrylamide
[89] [95], agarose [90] and nitrocellulose gels [96] [97] [98] [99] [100] [101], as well as
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poly(vinylidene fluoride) (PVDF) membranes [102] [103]). In addition, there exist more
specialized chemistries that are more difficult to categorize as they combine characteristics
of the two; while they do not provide a three-dimensional structure within which proteins
are retained, they incorporate some supramolecular assemblies [24]. Some examples
include avidin [105], streptavidin [84], nickel [92], dendrimer [106] [107], or polyethylene
glycol (PEG) slides [108]. These surfaces immobilize proteins through the covalent
attachment of epoxy or specialized affinity groups.
Numerous variables affect antibody microarrays including surface modifications, crosslinking strategies, spotting buffer compositions, blocking reagents, antibody
concentrations, and storage conditions [94] [77] [165] [166] [78]. Among two-dimensional
surfaces, poly-L-lysine and cross-linked silane slides perform best, displaying good
sensitivity and signal-to-noise ratios [94]. Nitrocellulose surfaces, on the other hand,
exhibited low signal-to-noise ratios with high signal intensities as well as high background
signals [94]. Similar studies, comparing limits of detection, coefficients of variation, and
storage characteristics for different commercially available slide chemistries determined
that in terms of overall array performance poly-L-lysine and aldehyde slides displayed the
best signal uniformity and signal-to-noise ratios [77]. Aldehyde silane, poly-L-lysine, or
aminosilane slides were also observed to produce superior result in an independent study
[83] . A comprehensive study evaluating 17 commercially available microarray surfaces
proposes a rigorous and quantitative system for comparing different surfaces based on
spot morphology, background noise, limit of detection, and reproducibility with 23
antibody assays [78].
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Microarray surfaces need to provide high surface areas for binding that enable high signalto-noise ratio and flexible immobilization chemistries. Oligomeric N-substituted glycines
(peptoids) are promising as biosensor interfaces due to their low immunogenicity, ease of
synthesis, highly customizable side chain chemistries, and the ability to form
supramolecular structures that can increase surface area [109]. Peptoids are bioinspired,
peptidomimetic polymers with a backbone structure closely resembling that of peptides,
but with the side chains appended to the amide groups rather than the α-carbons. This
structural modification prevents proteolytic degradation, making peptoids attractive as
biocompatible materials. However, this modification also removes the presence of
backbone amide hydrogens, which are critical for the formation of the hydrogen bond
linkages that stabilize beta sheets and helices in peptides. Despite these limitations,
secondary structures including turns, loops, and helices, as well as supramolecular
assemblies such as superhelices [167], nanosheets [168], nanotubes [169] and
microspheres [125] can be induced in peptoids upon the addition of specific side chains.
Peptoid helices have been demonstrated to form polyproline type-I-like helices, similar to
those of proteins, with a periodicity of three monomers per turn and pitch of
approximately 6 Å with as few as five monomer units [120].
In this study, we report the development of peptoid microsphere-coated glass substrates
for use in sandwich ELISA microarray. The morphology and uniformity of the coatings was
evaluated by SEM and the coating efficacy was analyzed by ELISA microarray with known
antibody assays. The peptoid microsphere-coated surfaces were found to exhibit higher
signal intensity and dynamic range as compared to commercially available microarray
surfaces.
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7.2. Materials and Methods
7.2.1. Materials
4-methoxybenzylamine and (S)-methylbenzylamine were purchased from Acros Organics
(Pittsburgh, PA). tert-butyl N-(4-aminobutyl)carbamate was purchased from CNH
Technologies Inc. (Woburn, MA). MBHA rink amide resin was purchased from
NovaBiochem (Gibbstown, NJ). Piperidine was purchased from Sigma-Aldrich (St. Louis,
MO). Test grade silicon wafers were purchased from University Wafer (South Boston, MA).
Poly-L-lysine and ultra clean glass microarray slides were purchased from Thermo
Scientific (Pittsburgh, PA). Disuccinimidyl suberate (DSS) and bis[sulfosuccinimidyl]
suberate (BS3) were purchased from Pierce (Rockford, IL, USA). Purified antibodies and
antigens were purchased from R&D Systems (Minneapolis, MN, USA). Blocking solution
containing 10 mg/ml casein in phosphate-buffered saline, pH 7.2 (PBS) was purchased
from Bio Rad Laboratories (Hercules, CA, USA). Tyramide Signal Amplification (TSA)
system, including streptavidin-conjugated horseradish peroxidase, amplification diluent,
and biotinyl tyramide, was purchased from Perkin Elmer (Wellesley, MA, USA). Alexa647conjugated streptavidin was purchased from Invitrogen Life Technologies (Gaithersburg,
MD). All other reagents were purchased from VWR (Radnor, PA). All chemicals were used
without further modifications unless otherwise specified.
7.2.2. Peptoid Synthesis
Peptoids were synthesized via the submonomer solid-phase method on rink amide resin, as
previously described [170]. Briefly, the resin was swelled with dimethylformamide (DMF)
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and the Fmoc protecting group on the resin was removed using a 20% solution of
piperidine in DMF. The resin-bound secondary amine was acylated with 0.4 M bromoacetic
acid (BAA) in DMF in the presence of N,N’-diisopropyl carbodiimide (DIC). Amine
submonomers were incorporated via an SN2 nucleophilic substitution reaction with
primary amine in DMF. The two-step bromoacetylation and nucleophilic substitution cycle
was repeated until all desired side chains were incorporated. The peptoid was cleaved
from the resin using a mixture of 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5%
triisopropylsilane and the acid was removed using a Heidolph Laborota 4001 rotating
evaporator (Elk Grove Village, IL). The peptoid was lyophilized to a powder using a
Labconco lyophilizer (Kansas City, MO) and diluted to a concentration of ~3 mg/ml in a
50:50 acetonitrile-water solution.
7.2.3. Peptoid Purification
Peptoids were purified using a Waters Delta 600 preparative high-performance liquid
chromatography (HPLC) instrument (Milford, MA) with a Duragel G C18 150 × 20 mm
column (Peeke Scientific, Novato, CA) and a linear gradient of 35-95% solvent B
(acetonitrile, 5% water, 0.1% TFA) in A (water, 5% acetonitrile, 0.1% TFA), over 60
minutes. Peptoids were confirmed to be >98% pure via analytical HPLC (Waters Alliance,
Milford, MA) with a Duragel G C18 150 × 2.1 mm column (Peeke Scientific) using a linear
gradient of 35 to 95% solvent D (acetonitrile, 0.1% TFA) in C (water, 0.1% TFA), over 30
minutes. Purified peptoid fractions were lyophilized and stored as a powder at -20 °C.
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7.2.4. Peptoid Characterization
Synthesis of the desired peptoid sequence was confirmed via matrix assisted laser
desorption/ionization time of flight (MALDI-TOF; Bruker, Billerica, MA) mass
spectrometry. Secondary structure was confirmed via CD spectrometry using a Jasco J-715
instrument (Easton, MD) at room temperature with a scanning speed of 20 nm/min and a
path length of 0.1 mm. The peptoid was dissolved in methanol at a concentration of 120 µM
because protic solvents have been demonstrated to help induce helical secondary structure
in peptoids. Each spectrum was the average of twenty accumulations.
7.2.5. Peptoid Microsphere Coatings
Peptoid microspheres were prepared by dissolving the peptoid in a 4:1 (v/v)
ethanol/water solution at a concentration of 5 mg/ml, as previously described [125]. Glass
slides (Erie Scientific, Portsmouth, NH) were outlined with an 8 x 2 array pattern using a
Barnstead Thermolyne microarray slide imprinter (Dubuque, IA) to create a hydrophobic
barrier for processing 16 wells per slide. The peptoid solution was applied to the glass
surfaces and allowed to dry at room temperature and 60% relative humidity. Coating
morphologies were visually assessed using a Phillips XL-30 scanning electron microscope
(SEM) (FEI, Hillsboro, OR).
7.2.6. Microarray Printing
ELISA microarray printing was performed at room temperature and 60% relative humidity
as previously described [138]. A GeSiM NanoPlotter 2.1 (Quantum Analytics, Foster City,
CA, USA) non-contact microarray printer with humidity control was used to spot the
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antibodies. Prior to spotting, the microsphere coated surfaces, and in some cases the polyL-lyisne slides, were treated with a 0.3 mg/ml solution of the homo-bifunctional crosslinker BS3 in PBS for 20 minutes to create a reactive site for covalent attachment via the
amine groups. After incubation, the slides were rinsed in nanopure water and dried in a
centrifuge. Capture antibodies were suspended in PBS to a concentration of 0.8 mg/ml and
~400 picoliters per spot were printed 500 um apart in quintuplicate on each array. Upon
completion, the antibodies were allowed to dry for an additional hour at 60% relative
humidity. The slides were blocked with 10 mg/ml casein in PBS and processed
immediately.
7.2.7. ELISA Microarray
ELISA Microarray was performed as previously described [138], with all incubation steps
performed in a closed humid chamber with gentle mixing on an orbital shaker (Belly
Dancer, Stovall Life Science, Greensboro, NC), in the dark, at room temperature. A two-step
wash procedure between processing steps was performed by submerging the slides twice
into PBS containing 0.05% Tween-20 (PBS-T). The slides were incubated with a mixture of
antigen standards in 1 mg/ml casein in PBS overnight. Standard curves were created using
a three-fold dilution series of the antigen mix along with an antigen-free blank for twelve
total dilutions. Following a wash cycle, the slides were incubated with biotinylated
detection antibody at 25 ng/ml in 1 mg/ml casein in PBS. The signal was amplified using
the TSA system following manufacturer instructions, and incubated with 1 μg/ml
Alexa647-conjugated streptavidin in PBS-T. Lastly, the slides were rinsed twice in PBS-T
and lastly in deionized prior to scanning.
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A GenePix Autoloader 4200AL (Molecular Devices, CA) laser scanner was used to image the
Alexa 647 fluorescence signal on the slides. The spot fluorescence intensity from the
scanned slide images was quantified using GenePix Pro 3.0 software. Standard curves were
created using ProMAT, a software program specifically developed for the analysis of ELISA
microarray data based on a four-parameter logistic curves model [139]. The values for the
lower limits of detection are calculated as the mean concentration plus three standard
deviations of the log-transformed spot intensity for the antigen-free blank. In order to
provide a value that is representative of all assays for comparisons, a relative limit of
detection value was calculated using the median value for all assay replicates on each
surface. Results shown, unless noted otherwise, encompass three replicate experiments
performed using slides that were coated, printed, and processed on independent occasions.
Statistical significance was assessed using a t-test with a 95% confidence intervals where
probabilities of p < 0.05 were considered statistically significant.
7.3. Results and Discussion
7.3.1. Peptoid Sequence Rationale
Our lab has previously shown that partially water-soluble, helical peptoids self-assemble
into microspheres [125]. The peptoid sequence, referred to as P3 (Figure 7.1.), includes
chiral, aromatic side chains on two faces of the helix to induce the formation of helical
secondary structure [131]. The third face of the helix, which offers considerable flexibility
of design, contains methoxy and amine groups to increase water solubility. The amine
groups also enables covalent linkage to and electrostatic interactions with the slide surface.
The secondary structure of P3 was determined by circular dichroism, which confirms poly56

proline type-I-like secondary structure (Figure S7.1. in Supplemental Information) [121].

Figure 7.1. Peptoid structure for the P3 sequence.
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7.3.2. Coating Characterization
The formation of uniform peptoid microsphere coatings is essential to reduce variability in
ELISA microarray assays. Coating morphology is directly linked to evaporation rate,
requiring careful monitoring of drying conditions to ensure uniform sphere distribution
and reproducible coatings. One issue observed in the formation of peptoid coatings is
perimetral intensive deposition, often referred to as the “coffee ring effect”, in which
denser coverage is observed at the perimeter of the coatings as compared to the center.
Previous studies have shown that this effect is reduced when samples are evaporated at a
constant contact area, which can be achieved by including surfactant in the microsphere
solution [171]. The addition of Tween-20 to the peptoid microsphere solution results in
improved coating uniformity, lessening perimetral microsphere deposition and allowing
for an even distribution of microspheres on the surface (Figure 7.2.). At concentrations
>0.1%, Tween-20 disrupts microspheres formation and alters microspheres size
distribution (Figure S7.2. in Supplemental Information).
Microarray results of the microsphere coated slides demonstrated very faint fluorescent
signals, indicative of a weak surface attachment of the antibodies. To enhance
immobilization, the peptoid microsphere coated surfaces were covalently attached. BS3
treatment greatly reduced the antibody loss at the surface due to the wash steps necessary
for processing the slides. Consistent with findings elsewhere [78], studies for all assays on
poly-L-lysine surfaces demonstrate no significant difference when assessing antibodies
immobilized on non-covalent surfaces as compared to those attached covalently (Figure
S7.3. in Supplemental Information). This supports the notion that the increase in intensities
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associated to the microsphere coatings occurs as a result of the increase in surface area
available for binding. It is also important to note that although higher backgrounds are
observed with the coatings, such background fluorescence was observed independent of
covalent treatment.

Figure 7.2. Peptoid microsphere coated glass surfaces. Peptoids were dissolved in a 4:1
(v/v) ethanol/water solution at a concentration of 5 mg/ml. The peptoid solution was
applied to the glass surfaces and allowed to dry at room temperature and 60% relative
humidity.
7.3.3. Coating Efficacy for ELISA Microarray
The efficacy of the peptoid microsphere coatings was evaluated by ELISA microarray with
four antibody assays, previously shown to have good assay sensitivity and specificity and
low cross-reactivity in multiplexed ELISA microarray (Table 1) [117]. The performance of
the surfaces was evaluated based on spot morphology, signal to noise ratio, limit of
detection, and concentration dynamic range. Signal intensities were evaluated by
comparing single concentration assays on peptoid-based microsphere coated blocks with
‘uncoated’ poly-L-lysine surfaces. Single point antigen concentrations correspond to the
third dilution of the three-fold standard curve dilution series (i.e. approximately 11% of the
maximal concentration), previously shown to provide a strong signal intensity near
59

saturation and in the upper usable range of the standard curve [66].
Spot morphology is dependent on the characteristics of the surface. The increased
topographical complexity of three-dimensional surfaces presents its challenges. Although
the spot morphology on peptoid microspheres is not as crisp as those on the twodimensional poly-L-lysine surfaces, they are greatly improved over other threedimensional surfaces [78]. As is the case with other three-dimensional slide surfaces, the
peptoid microsphere coated surface exhibits higher backgrounds of fluorescence as
compared to the two-dimensional surface (Figure 7.3.B). Despite the increased background
signal, the signal-to-noise ratio for the peptoid microsphere coating is the same as or
higher than the poly-L-lysine coating.
Table 7.1. Summary of the results detailing the maximal concentration of antigens, lower,
upper bound, dynamic range concentrations, and single point signal intensities (11% of the
maximal concentration) for the ‘uncoated’ poly-L-lysine surfaces and peptoid-based
microsphere coated surfaces antigens for all 5 different assays: CD14 (cluster of
differentiation 14), GFP (green fluorescent protein), HGF (hepatocyte growth factor), and
RANTES (regulated on activation normal T cell expressed and secreted). Statistical
significance was assessed using a t-test with a 95% confidence intervals where *p<0.05,
**p<0.01, and ***p<0.001 for assays on uncoated vs. coated surfaces.
Assay

Max Conc.

Limit of Detection

Dynamic Range

Signal/Noise Ratio

Uncoated

Coated

Uncoated

Coated

Uncoated

Coated

CD14 **

2500

1.9

2.0

527.8

530.2

21.4

21.3

GFP ***

500

0.2

0.7

80.0

97.0

17.8

30.5

HGF ***

1000

0.3

2.7

135.3

492.8

20.7

30.6

RANTES ***

500

0.4

0.3

64.6

264.2

15.8

16.8
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Figure 7.3. A) Images of fluorescence for GFP and HGF with BS3 treatment on a) peptoid
microsphere coated glass surfaces, b) uncoated poly-L-lysine surfaces. B) Comparison of
background fluorescence for the peptoid microsphere coated glass surfaces and ‘uncoated’
poly-L-lysine surfaces. Columns and cross-bars represent the means and standard
deviations, respectively, of the median spot backgrounds on ‘uncoated’ poly-L-lysine slides
and ‘coated’ peptoid microsphere surfaces across three replicate experiments. C)
Comparison of single point signal intensities (11% of the maximal concentration) for all
antibody assays (CD14, GFP, HGF, and RANTES) on peptoid microsphere coated glass
surfaces with BS3 treatment and uncoated poly-L-lysine surfaces. Columns and cross-bars
represent the means and standard deviations, respectively, of the signal intensities on
‘uncoated’ poly-L-lysine slides and ‘coated’ peptoid microsphere surfaces printed and
processed at the same time, and representative of additional replicate studies.
The performance of the peptoid microsphere coatings was compared to commercial polyL-lysine surfaces, which are widely used for antibody assays [126] and provide a similar
chemistry for antibody attachment as the peptoid microsphere coatings. As compared to
poly-L-lysine slides, peptoid microsphere coated surfaces consistently displayed stronger
61

signal intensities, averaging a two-fold increase, under identical processing conditions
(Figure 7.3.C and Table 7.1.). This observation is clear for all assays and consistent whether
the comparisons are based on a single concentration point (Figure 7.3.C) or over the full
standard curve (Figure 7.4.).

Figure 7.4. Standard curves for HGF on ‘uncoated’ poly-L-lysine slides and ‘coated’ peptoid
microsphere surfaces on a log 10 vs log 3 plot. Results are representative of the trends
observed across all antibody assays (see Figure S7.4. in Supplemental Information). Data
points and cross-bars represent the means and standard deviations, respectively. The
standard curves encompass data from all three replicate experiments performed using
slides that were coated, printed, and processed on independent occasions.
The limit of detection is a direct assessment of assay sensitivity, in other words the lowest
concentration that can be reliably detected. Evaluation of surface performance is based on
previously published methods, where relative limit of detection below 2 is ‘superior’,
between 2 and 4 is ‘normal, and above 4 is ‘poor’ [78]. Despite the larger standard
deviations at low antigen concentration for the peptoid microsphere coatings they are
rated in the superior category with a score of 0.9 ± 0.5 as compared to a score of 0.8 ± 0.3
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for poly-L-lysine slides in our study. These values are comparable to published values for
commercially available slides including poly-L-lysine (0.7 ± 0.1), aminosilane (1.3 ± 0.6),
aldehyde silane (1.1 ± 0.4), epoxysilane (1.2 ± 0.6), Slide E (0.8 ± 0.4), and Full Moon (1 ±
0.7) [78].
As hypothesized, the peptoid microsphere coatings have increased dynamic range as
compared to poly-L-lysine slides (Table 1). ProMAT outlines the useful range of the
standard curves by defining the lower limits of detection and upper concentration bound.
As the standard curve for HGF in Figure 7.4. demonstrates, and Table 1 details for all
assays, there exists an increase in the concentration dynamic ranges observed for the
peptoid microsphere coated surfaces as compared to ‘uncoated’ poly-L-lysine surfaces.
Though the extent of the increase varies (2.4 for CD14, 17 for GFP, 357.5 for HGF, and 199.6
pg/ml for RANTES), this increase is consistently observed for most assays.
Although the performances of the assays are directly associated to the characteristics of the
surfaces, it is important to recognize the importance of the protocols by which the assays
are spotted, blocked, and processed for fluorescent scanning. It is quite possible that the
performance of the microsphere coated surfaces hold ample room for improvement. For
instance, adjustments to the spotting protocols, in particular the spotting buffer, offer
significant potential. Many of the more complex three-dimensional surfaces often require
specialized spotting buffers. We found that the addition of 5% glycerol (Figure S7.5. in
Supplementary Information) can improve spot morphology, one of the main detriments the
microsphere coatings suffer. Increases in the density of spotting buffers limits spot
spreading, decreasing spot diameters, and thus improving the overall spot morphology.
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While more densely printed arrays yield high signal intensities, they also complicate
surface evaluations as it inserts an additional variable to the comparisons. Results on these
coatings are promising because they validate peptoid coatings as viable material for
biosensor applications, as well as demonstrate an increase in the dynamic range associated
to the increased binding affinity these surfaces offer.
7.4. Conclusion
High-throughput demands in protein detection (including ELISA microarray and
biosensors) require the selection and development of optimized support surfaces that
allow for more generally applicable and direct immobilization procedures. While high
binding affinities are imperative to prevent antibody loss and ensure robust attachment,
the challenge lies in designing a microarray support that accommodates proteins of varying
characteristics and provides a non-denaturing environment to preserve the active form of
the protein. We have evaluated the use of peptoid microsphere coatings as a novel surface
for the improvement of sandwich ELISA microarrays. This peptoid-based, threedimensional coating offers a customizable, water insoluble, biocompatible interface that
increases the surface area available for protein binding. The efficacy of the coating was
assessed in terms of its overall array performance as compared to commercially available
poly-L-lysine coated surfaces [81] [94]. The coatings allowed for strong covalent antibody
attachment and performed well in terms of limits of detection. The increase in surface area
enables higher protein binding capacities as compared to two-dimensional poly-L-lysine
surfaces. Although the peptoid microsphere coatings displayed higher background
fluorescence and coefficients of variation, higher signal-to-noise ratios were observed
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compared to poly-L-lysine surfaces.
The peptoid microsphere coatings provide an exciting new interface for a wide range of
biosensor applications. Results suggest that existing biosensor protocols and procedures
(printing, blocking, processing, and storage) can be readily applied to peptoid microsphere
coatings and that the coatings outperform state-of-the art surfaces such as poly-L-lysine.
The robust peptoid microsphere coated surface provides a versatile platform that can be
easily customizable. It offers the benefits that come with an increased surface area for
binding, while at the same time allow for use of familiar chemistries that are established for
both protein microarray and biosensor applications.

65

7.6. Supplemental Information
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Figure S7.1. Circular dichroism spectra of peptoid showing a poly-proline type-1-like
helical secondary structure. CD spectra were taken at room temperature with a scanning
speed of 20 nm/min and a path length of 0.1 mm. The peptoid was dissolved in methanol at
a concentration of 120 µM.

Figure S7.2. Effects of Tween-20 on microsphere coatings: A) 0.001%, B) 0.01%, C) 0.1%,
and D) 1% by volume.
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Figure S7.3. Comparison of signal intensities across all antibody assays (CD14, GFP, HGF,
ICAM, and Rantes) on uncoated poly-L-lysine surfaces based on non-covalent attachments
and covalent attachments via BS3 treatment.
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Figure S7.4. Standard curves for all antibody assays on ‘uncoated’ poly-L-lysine slides and
the peptoid-based microspheres coated glass surfaces on a log 10 vs log 3 plot.

Figure S7.5. Improvement on spot morphology upon the addition of 5% glycerol (bottom)
to the GFP 1mg/ml casein in PBS spotting buffer.
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8. Peptoid Microsphere Coatings: The Effects of Helicity, pH, and Ionic Strength
8.1. Introduction
Natural polymers have inspired the development of synthetic materials that mimic the
fundamental molecular features that allow for the diverse array of functions found in
nature [109]. Proteins have a myriad of unique functional properties, providing for
example, binding and catalytic sites that together enable molecular recognition. However,
as biomaterials peptides present a major drawback due to proteolytic degradation and as a
result are limited in their potential for biomedical and therapeutic applications [110].
Efforts to overcome these limitations have led to the design and development of innovative
peptidomimetic oligomers [111] [112] [113] [114] [115] [116]. These synthetic polymer
analogs predominately exploit structural similarities in order to allow for the mimicry of
bioactive functionalities. Bioactive roles however, are often determined by the unique
ability of peptides to self-assemble into complex, sequence-specific three-dimensional
secondary structures [117]. Specific peptidomimetic oligomers, commonly referred to as
foldamers [118], display well-defined secondary structures, are therefore of great interest
for use in biomaterials.
Peptoids are a form of bio-mimetic synthetic polymers that closely resemble peptides, but
have the side chains attached to the backbone amide nitrogen rather than to the α-carbon
as in peptides. Like peptides, peptoids can be constructed via solid-phase synthesis [122]
following a submonomer method that provides a robust and highly efficient platform for
synthesis, enabling precise sequence control. Synthesis follows a carboxy to amino
direction, in which each monomer cycle includes (1) acylation and (2) nucleophilic
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substitution [121]. Functional moieties are introduced by the incorporation of
commercially available primary amines, enabling access to more than 300 side chain
chemistries [109]. Monomer coupling efficiencies of >98% [123] allow for the precise
sequence-specific synthesis of polymer chains surpassing over 300 monomeric subunits in
length [124].
The seemingly minor modification to the backbone has important implications to peptoid
structure and Function. Peptoids are not susceptible to proteolytic degradation, making
them a promising alternative to peptides for therapeutic applications where proteolysis is
of major concern. However, the backbone modification also prevents backbone hydrogen
bonding, which, although critical for the formation of secondary structure in peptides can
be overcome by including specific side chains to form secondary structures such as turns
[172] [173], loops [174], and helices [175] [123] [120] [132] [133] that in turn allow for
the formation of supramolecular assemblies [167] [149] [176] [127] [168] [125]. Stable
helices can be formed by peptoids as short as five monomer units with circular dichroism
(CD) spectra that strongly resemble those of protein α-helices [117]. NMR studies show
that peptoids have a helical structure similar to polyproline type-I helices in proteins, with
a periodicity of three residues per turn and a pitch of ~6 Å [120].
Past work in the Servoss lab has focused on the effect of various parameters on the selfassembly of peptoids into microspheres including water solubility, helical content, charge
placement, and side chain bulk [125]. It was demonstrated that helicity and partial water
solubility are crucial for microsphere formation. Furthermore, peptoid sequences with
alternating opposite charges on one face of the helix produce smaller microspheres (~0.3
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μm) as compared to those with only positive charges (~1.5 μm). It is believed that the
opposite charges interact to form tighter helices, which result in the smaller
supramolecular assemblies observed [125]. The microspheres formed are orders of
magnitude larger than a single peptoid helix (∼24 Å), supporting the theory that larger
peptoid groupings are formed by stacking of the chiral aromatic groups [125]. Aromatic
stacking has been observed in similar types of supramolecular assemblies in both peptides
and peptoids [126] [127] [128] [129] [130]. Further work investigated the factors that
affect the reproducible formation microsphere coatings including solvent effects,
administration technique, and drying conditions [131].
The present study reports the effect of peptoid chain length (and in turn helicity) as well as
pH and ionic strength on the formation and robustness of peptoid microsphere coatings.
The morphology of the microsphere coatings was analyzed via SEM. The studies show that
variations in chain length lead to changes in microsphere size and size distribution. The
morphology of microsphere coatings deteriorated at low ionic strengths and pH, however
they are extremely robust at physiological conditions.
8.2. Materials and Methods
8.2.1. Materials
(S)-methylbenzylamine and 4-methoxybenzylamine were purchased from Acros Organics
(Pittsburgh, PA). tert-butyl N-(4-aminobutyl)carbamate was purchased from CNH
Technologies Inc. (Woburn, MA). MBHA rink amide resin was purchased from
NovaBiochem (Gibbstown, NJ). Piperidine was purchased from Sigma-Aldrich (St. Louis,
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MO). Test grade silicon wafers were purchased from University Wafer (South Boston, MA).
Poly-L-lysine, amino silane, and ultra clean glass microarray slides were purchased from
Thermo Scientific (Pittsburgh, PA). Disuccinimidyl suberate (DSS) was purchased from
Pierce (Rockford, IL, USA). All other reagents were purchased from VWR (Radnor, PA). All
chemicals were used without further modifications unless otherwise specified.
8.2.2. Peptoid Synthesis
Peptoids were synthesized via the submonomer solid-phase method on rink amide resin
[122]. The resin was initially swelled with dimethylformamide (DMF), and the Fmoc
protecting group on the resin was removed using a 20% solution of piperidine in DMF. The
resin-bound secondary amine was acylated with 0.4 M bromoacetic acid (BAA) in DMF, in
the presence of N,N’-diisopropyl carbodiimide (DIC), mixing for 1 minute. Amine submonomers were incorporated via an SN2 nucleophilic substitution reaction with 0.5M
primary amine in DMF, mixing for 2 minutes. The two-step bromoacetylation and
nucleophilic substitution cycle were repeated until all desired side chains have been
incorporated. The peptoid was cleaved from the resin using a mixture of 95%
trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane. The acid was removed
using a Heidolph Laborota 4001 rotating evaporator (Elk Grove Village, IL). The peptoid
solution was lyophilized to a powder using a Labconco lyophilizer (Kansas City, MO). The
peptoid powder was diluted to a concentration of ~3 mg/ml in a 50:50 acetonitrile-water
solution.
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8.2.3. Purification
Peptoids were purified using a Waters Delta 600 preparative high-performance liquid
chromatography (HPLC) instrument (Milford, MA) with a Duragel G C18 150 × 20 mm
column (Peeke Scientific, Novato, CA) and a linear gradient of 35-95% solvent B
(acetonitrile, 5% water, 0.1% TFA) in A (water, 5% acetonitrile, 0.1% TFA), over 60
minutes. Peptoids were confirmed to be >98% pure via analytical HPLC (Waters Alliance,
Milford, MA) with a Duragel G C18 150 × 2.1 mm column (Peeke Scientific, Novato, CA)
using a linear gradient of 35 to 95% solvent D (acetonitrile, 0.1% TFA) in C (water, 0.1%
TFA), over 30 minutes. Purified peptoid fractions were lyophilized using a and stored as a
powder at -20 °C.
8.2.4. Characterization
Synthesis was confirmed via matrix assisted laser desorption/ionization time of flight
(MALDI-TOF) mass spectrometry (Bruker, Billerica, MA). Secondary structure was
confirmed via CD spectrometry using a Jasco J-715 instrument (Easton, MD) at room
temperature with a scanning speed of 20 nm/min and a path length of 0.2 mm. The peptoid
was dissolved in methanol at a concentration of 60 µM. Each spectrum was the average of
twenty accumulations.
8.2.5. Peptoid Microsphere Coatings
Peptoid microspheres were prepared by dissolving the peptoid in a 4:1 (v/v)
ethanol/water solution at a concentration of 5 mg/ml. The peptoid solution was applied
using a pipette onto a glass surface and allowed to dry at room temperature and 60%
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relative humidity for an hour. Coating morphologies were visually assessed using a Phillips
XL-30 environmental scanning electron microscope (SEM; FEI, Hillsboro, OR) at the
Material Characterization Facility.
8.2.6. Microsphere Analysis
Particle analysis was performed using ImageJ software (National Institute of Health, MD).
Noise reduction through a fast Fourier transform (FFT) band-pass filter normalization. This
eliminates low- and high-spatial frequencies and transforms the original SEM images to a
two-dimensional representation of its frequencies. The images were converted to an 8-bit
grayscale and binarized adjusting the white and black threshold to optimize particle
contrast with the background. Lastly, a standard watershed algorithm was used to separate
fused markers.
8.3. Results and Discussion
8.3.1. Peptoid Sequence
The peptoid sequence used in this study is based on that previously shown to form
microspheres [125] and is referred to as P3 (Figure 8.1.). The addition of chiral aromatic
side chains in two faces of the helix sterically induces the formation of a helical secondary
peptoid structure (Figure 8.1.). The third face of the peptoid helices allows for the
incorporation of more ample chemistries. The P3 sequence, contains side chains with
amine and methoxy groups to increase water solubility, as partial water solubility is crucial
for microsphere formation. The amine groups facilitate surface attachment, via covalent
linkage and electrostatic interactions. To analyze the effects of chain length on microsphere
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formation, we prepared four different chain lengths inspired in the P3 sequence (Figure
8.1.) used in previous studies, which essentially repeats a 6-monomer unit sequence twice.
For such studies, we synthesized a 6 monomeric unit pepotid sequence (6mer), a 12
monomer sequence (the original P3 12mer), a 18 monomer sequence (18mer), and a 24
monomer peptoid sequence (24mer) all assembled by repeating the 6mer peptoid
sequence 2, 3, and 4 times respectively.

Figure 8.1. (A) Linear peptoid sequence to the n reapeat with n equal to 1 (6mer MW: 968),
2 (12mer MW: 1919), 3 (18mer MW: 2870), and 4 (24mer MW: 3821). (B) Helical
representation of the three faces of the 12mer peptoid sequence.
8.3.2. Chain Length Effects
Previous studies have shown that increasing the number of chiral side chains in a peptoid
sequence results in a more stable helical secondary structure [117]. In this study, peptoid
chain length is varied to alter helicity and ultimately microsphere size. We hypothesize that
larger peptoid sequences exhibiting tighter helices will form more closely packed
supramolecular assemblies, and thus smaller microspheres, while shorter peptoid
sequences exhibiting less structured helices will form less closely packed supramolecular
assemblies, and thus larger microspheres. CD spectra (Figure 8.2.) for all of the peptoids
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exhibit a maximum near 193 nm and two minima near 208 and 222 nm, commonly
indicative of poly-proline type-I-like peptoid helices [121]. We conclude that, analogously,
the extent of helicity increases with peptoid length, as evidenced by the increased ratio of
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the 222 and 208 nm peak intensities [177].
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Figure 8.2. Circular dichroism spectra showing a poly-proline type-I-like helical secondary
structure for the peptoids in methanol at 60 µM.
SEM analysis of the peptoid coatings formed under standard conditions show that
microspheres formed for the 12, 18, and 24mer peptoids and no microspheres were
observed for the 6mer peptoid (Figure 8.3.). No differences were observed with changes in
these variables, and the 6mer peptoid did not form microspheres under any conditions
tested. The average microsphere diameters were 1.59 ± 0.22, 1.19 ± 0.24, and 0.60 ± 0.28
μm for the 12, 18, and 24mer peptoids, respectively, supporting our hypothesis that
microsphere size decreases with increasing helicity. While there was a size distribution
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present for all of the chain lengths (Figure 8.4.), the larger microspheres formed by the
12mer peptoid were the most uniform.

Figure 8.3. Chain length effect on microsphere formation: A) 6mer, B) 12mer, C) 18mer,
and D) 24mer. The microspheres were formed by dissolving the peptoid in a 4:1 (v/v)
ethanol/water solution at a concentration of 5 mg/ml. The peptoid solution was applied to
glass surfaces and allowed to dry at room temperature and 60% relative humidity.

Figure 8.4. Microsphere size distribution present for each peptoid chain length: A) 12mer,
B) 18mer, and C) 24mer, and D) 24mer.

77

8.3.3. Coating Robustness
In order to be practical in biosensor applications, the peptoid microsphere coatings must
be robust under various conditions. The robustness of the peptoid microspheres were
assessed in conditions common to ELISA microarray including 10 mg/mL casein in
phosphate-buffered saline (PBS; pH 7.3, ionic strength 150 mM), 0.05% Tween in PBS
(PBS-T; pH 7.3, ionic strength 150 mM), 0.003% hydrogen peroxide in 0.1M sodium borate
(pH 8.2, ionic strength 600 mM), and nanopure water (pH ~7, ionic strength ~0 mM). The
microspheres were able to withstand all conditions with minimal effect to morphology and
total coverage, with the exception of water (Figure 8.5.). After exposure to water for 30
minutes the microspheres appeared to disintegrate and lift from the service. While the
peptoid microspheres appear to start to solubilize in water after only 30 minutes, they are
robust in PBS for up to 2 months (see Figure S8.1. in Supplemental Information). Based on
these preliminary findings, we have investigated the effects of pH and ionic strength on
peptoid microsphere coating robustness.

Figure 8.5. SEM images of the peptoid microspheres (A) before incubation, (B) after 24
hour incubation in PBS, (C) after 30 minute incubation in water incubation with inset (D)
showing a high magnification peptoid microsphere. The microspheres were formed by
dissolving the peptoid in a 4:1 (v/v) ethanol/water solution at a concentration of 5 mg/ml.
The peptoid solution was applied to glass surfaces and allowed to dry at room temperature
and 60% relative humidity.
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pH. In order to determine the effect of solvent pH on peptoid microsphere coating
robustness, morphology and coating coverage was assessed by SEM following incubation in
PBS and water at different pH values. Coatings exposed to PBS or water with pH of 7 or
greater are robust, with no significant differences in microsphere morphology or coating
coverage (Figure 8.6. panels A-E). As the solvent approaches acidic conditions (pH less than
7), the microsphere morphology and coating coverage deteriorate (Figure 8.6. panels F-I).
This observation was consistent whether the pH effect was analyzed in PBS or water at
similar pH values (see Figure S8.2. in Supplemental Information). While we do not
anticipate changes in pH of the solvent environment to change the charge state of peptoid.
Acidic conditions increase peptoid solubility. Peptoids with ionizable side chains have been
demonstrated to destabilize in response to pH-depenent changes in aqueous solvent
environment [123] [178]. It would be interesting to complete a more thorough CD studies
on the effects of pH on secondary structure for our particular peptoid sequences.
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Figure 8.6. SEM images demonstrating the effect of pH on sphere morphology after 30
minutes in PBS, pH values range from: A) pH 11, B) pH 10, C) pH 9, D) pH 8, E) pH 7, F) pH
6, G) pH 5, H) pH 4, and I) pH 11.
Ionic Strength. The effect of ionic strength on peptoid microsphere coating robustness
was assessed via SEM following incubation in various ionic strength solutions (0-500 mM)
at either pH 6.7 (water) or pH 7.3 (PBS). Following incubation in water solutions, SEM
images demonstrate no considerable effect on microsphere morphology at ionic strengths
greater than 150 mM (Figure 8.7. panels A-C). As the ionic strength decreases, microsphere
morphology and coverage begins to deteriorate (Figure 8.7. panels D-F). At ionic strengths
less than 150 mM the microspheres appear to fuse together and as ionic strength decreases
the microspheres detach from the surface. Experiments evaluating the effect of ionic
strength in PBS (pH 7.3) demonstrate similar trends, with the peptoid microspheres
remaining unaffected at ionic strengths above 150 mM (Figure 8.8.).
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As compared to peptide helices, peptoid helices have much more stable conformational
assemblies. As a result, helical peptiod have been demonstrated to be much less susceptible
to their solvent conditions. In peptides, increasing the ionic strength of the solvent has
been demonstrated to stabilize secondary structure in a variety of ionic polypeptides by
screening the electrostatic repulsion between side chains [179] [180] [181]. Strongly
charged helical peptides are completely destabilized in low ionic strength environments
[182]. Interestingly, a similar dependence has been observed in high-ionic strength
solutions in peptoids [133] [178]. We believe that the screening of charge-charge repulsive
interactions at higher ionic strengths preserve the helical secondary that is crucial for
microsphere formation.

Figure 8.7. SEM images demonstrating the effect of ionic strength on sphere morphology
after 30 minutes. A) 500 mM , B) 250 mM, C) 150 mM, D) 100 mM, E) 50 mM, and F) 0 mM
ionic strength in water.
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Figure 8.8. SEM images demonstrating the effect of ionic strength on sphere morphology
after 30 minutes. A) 500 mM, B) 250 mM, and C) 150 mM ionic strength in PBS.
8.4. Conclusion
We have evaluated the use the effect of peptoid chain length as well as pH and ionic
strength on the formation and robustness of peptoid microsphere coatings. We have found
that sphere size can be tuned by varying peptoid chain length. CD spectra as a function of
peptoid chain length suggests that larger sequence increase the degree of helicity. We
believe that larger peptoid sequences form tighter, more stable helices, which enable the
formation of smaller supramolecular assemblies. While the microsphere deteriorated at
low ionic strengths and pH, the coatings display outstanding robustness at physiological
conditions. Acidic conditions increase the peptoid low aqueous solubility. We believe that
solvent counterions at higher ionic strengths screen the electrostatic repulsion between
side chains and stabilize secondary structure, shielding the micropsheres.
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8.6. Supplemental Information

Figure S8.1. SEM images demonstrating the robustness of the microsphere in PBS after 2
months.

Figure S8.2. SEM images demonstrating the effect of pH on sphere morphology after 30
minutes in water, pH values range from: A) no incubation, B) pH 11, C) pH 8, D) pH 7, E) pH
6, and F) pH 3.
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9. Conclusions
The search for non-invasive, high-throughput, and cost-effective tools for early stage
disease detection has led to the development of biosensor technologies of increasing
complexity. Advances in biomarker technologies require the development of support
surfaces that allow for more versatile immobilization procedures. The challenge lies in
designing an interface that accommodates molecules of diverse characteristics in a manner
that retains their innate activities. Surfaces need to provide biocompatible and bioresistant
interfaces, that offer high surface areas for binding, and enables the incorporation of
diverse chemistries. We believe that the use of peptoids as the basis for the deposition of
uniform microsphere coatings offers a promising means to the attainment of such
interfacial characteristics.
We have studied the variants affecting the formation of the peptoid microspheres, and their
deposition into uniform coatings. We have found that varying peptoid chain length allows
for the rational tuning of microsphere size. We have demonstrated that the peptoid
microsphere coatings are extremely robust for applications at physiological conditions. We
have evaluated the use of peptoid microsphere coatings as a novel surface for ELISA
microarrays. The peptoid-based coatings increase the surface area for protein binding, and
allow for robust chemistries of attachment. While the coatings exhibited higher
background fluorescence and coefficients of variation, they performed well in terms of
limits of detection and signal-to-noise ratios compared to some of the best microarray
surfaces commercially available. We believe that peptoid microsphere coatings provide a
robust, biocompatible, versatile new interface that can be easily customized in design and
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surface modified for a wide range of biosensor applications.
10. Future Work
It is important to note that these studies were in many cases performed under very
particular set of conditions. Valuable insight that could that could elucidate a more
complete understating of our peptoid sequence likely lies in the synthesis of a different
peptoid sequence. It would be interesting to complete a more thorough study of the effect
of pH and ionic strength on secondary structure and its effect of the observed
morphological changes. A more hydrophilic variant of our P3 peptoid would likely need to
be synthesized for CD studies. Similarly, it would be interesting to assess whether the
effects seen would remain for peptoids with non-ionizable side chains. As well as assess
whether different acids would result in similar morphological variations. It would be
valuable to assess whether differences in osmotic pressure are responsible for the changes
seen at different ionic strengths. As well as determine, potentially by measuring the
surfaces zeta potential whether the charged sidechains are preferentially facing the outer
surface of the microspheres. The covalent immobilization of antibodies on the surface of
this microspheres via the amine groups suggests of their surface presence. In regard to the
use of the peptoid microsphere coating for microarray applications, I believe there is
considerable room for improvement, in particular by further optimizing pre-treatment and
blocking buffers in order to reduce background fluorescence, as well as improve spot
morphologies and further raise signal intensities upon the addition of different additives,
such as glycerol, to the printing buffers.
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13. Appendix: Submonomer Structures

(S)-Methylbenzylamine

4-Methoxybenzylamine

Tert-butyl N-(4-aminobutyl)carbamate
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